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Abstract 
Protein products of the Early Region 1A (E1A) gene in human adenovirus 5 (HAdV-5) are the 
first viral proteins expressed upon adenovirus infection. E1A disrupts many cellular 
physiological events by binding to and regulating an impressive number of host factors. Of 
particular interest is BS69, a repressor of E1A transactivation. Due to the strong interaction 
observed between E1A and BS69, I hypothesize that these two proteins function together to 
disrupt gene expression within an infected cell.   
Using in silico modelling and a series of yeast two-hybrid assays, I determined that residues 
112-119 of HAdV-5 E1A is the minimal interacting region for BS69. This interaction is 
conserved in HAdV-5, 9, and 12 from species C, D, and A. Furthermore, I found that the 
MYND domain of BS69 is both necessary and sufficient to interact with and inhibit E1A-
mediated transactivation in a mechanism dependent on the fidelity of the PXLXP motif and 
the adenovirus species. Therefore, I have found that BS69 physically interacts with E1A to 
disrupt gene transcription in mammalian cells. Future studies will reveal the effects of the E1A-
BS69 interaction on viral growth and regulation of viral and host genes.  
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1 Introduction 
 
Viruses are obligate intracellular parasites. It is not known how viruses originated, and it 
is still unclear if viruses are considered living organisms. At the most basic level, viruses 
are composed of a DNA or RNA genome encased within a proteinaceous capsid. The viral 
genome encodes structural and functional proteins to help with infection and replication. 
Some “deluxe” viruses are also covered by a lipid envelope. Viruses exist in all shapes and 
sizes, and infect organisms from all domains of life. They range from the tiny Circovirus, 
which can have a genome of less than 1800 nucleotides and a capsid of 15nm in diameter, 
to the humongous Pithovirus, which can have a genome of over 600 000 nucleotides and a 
capsid of up to 1500nm in length. Viruses are diverse and fascinating, and are intricately 
intertwined with the evolution of their host.  
Viruses were discovered in the early 1900s and have since played a pivotal role in the 
history of healthcare and biomedical research. Viruses cause many devastating diseases 
including smallpox and polio, and are thus an intensively studied topic. Because viruses 
have co-evolved extensively with their hosts, virus research has also taught us many 
lessons in cell biology. One specific example is the identification of mRNA splicing, which 
is a crucial cellular process discovered through examination of the adenovirus genome. 
With a relatively small genome and limited coding capacity, viruses also have the 
challenging task of overcoming host immunity and repurposing the cell to become 
conducive for viral replication. Thus, targets of viral proteins are likely critical cogs in the 
molecular machine.  
This project is focused on better understanding the biology of human adenoviruses and 
how they interact with the host. Specifically, we examine the components and effects 
resulting from the interaction between the adenovirus E1A protein and the host 
transcription regulator, BS69. From this project, we hope to learn more about viral-host 
interactions and to better characterize this mechanism of viral gene regulation. 
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1.1 Adenoviruses 
1.1.1 Discovery and Classification of Adenoviruses 
Adenoviruses were discovered by two separate groups in search of a causative agent of 
respiratory disease in 1953 and 1954 (Hilleman & Werner, 1954; Rowe et al., 1953).  Rowe 
et al. found a cytopathic agent isolated from human adenoid tissue that caused tissue 
degeneration in culture, while Hilleman and Werner isolated an agent with similar 
cytopathic effects from throat washings of an army recruit with primary atypical 
pneumonia (Hilleman & Werner, 1954; Rowe et al., 1953). These cytopathic agents were 
later determined to be viruses, and were named adenovirus in 1956 after the source, human 
adenoid tissue, from which the original isolate was found (Enders et al., 1956; Huebner et 
al., 1954).  
Adenoviruses are classified under the family Adenoviridae and branch into five genera: 
Atadenovirus, Aviadenovirus, Ichtadenovirus, Mastadenovirus, and Saidenovirus. Human 
adenoviruses (HAdV), along with adenoviruses that infect other mammals and vertebrates, 
are classified under the Mastadenovirus genus. Mastadenoviruses are further categorized 
into 7 species, adenovirus species A through G, based on biological properties such as 
hemagglutination groups, oncogenic potential, and genome sequence homology (Table 
1.1). Furthermore, there are currently 57 accepted human adenovirus types (HAdV-1 to 
57) distributed amongst these 7 adenovirus species. The newest species is species G, with 
HAdV-52 being the only member, while the newest type is HAdV-57 (Jones et al., 2007; 
Walsh et al., 2011). Human adenovirus types were historically distinguished based on 
resistance to neutralization by antisera against other adenovirus types. However, more 
recent techniques focus on protein or nucleotide sequence alignment in the main type-
specific epitopes, namely loop 1 and loop 2 of the hexon protein, involved in virus 
neutralization tests (Madisch et al., 2005). A ≥1.2% genetic divergence of loop 2 from the 
closest adenovirus prototype, or ≥2.4% genetic divergence in combination with ≥4.2% 
amino acid divergence of loop 1 from the closest prototype is necessary to support the 
identification of a new adenovirus type (Madisch et al., 2005). Other methods of 
adenovirus typing include sequence comparison of fiber knobs and hemagglutinin 
inhibition testing (Madisch et al., 2005). 
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Table 1.1. Properties of the seven human adenovirus species. Table showing 
hemagglutination group, example HAdV types, tumorigenicity in animals, 
transformation in tissue culture, genome percent GC, and infection/disease type of the 
seven HAdV species. HAdV-5 of species C is the most studied type, and the focus of this 
thesis. Table was adapted from (Berk, 2007), infection/disease type from (Ghebremedhin, 
2014), and information of HAdV species G from (Jones et al., 2007). 
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1.1.2 Human Adenovirus Virion Structure 
HAdV are non-enveloped viruses that are 80-110nm in diameter and encased by an 
icosahedral nucleocapsid composed of 252 subunits (Figure 1.1). 240 of these subunits are 
hexon capsomeres, while 12 are penton capsomeres. Hexon capsomeres are homotrimers 
that include up to 9 hypervariable loops that make up one of the major adenovirus type-
specific antigenic regions (Russell, 2009). These capsomeres are surrounded by 6 other 
penton or hexon subunits and form the 20 faces of the icosahedral nucleocapsid (San 
Martín, 2012). Penton capsomeres are homopentamers and include an arginine-glycine-
aspartic acid, or RGD, motif used to facilitate virus internalization via attachment to 
cellular integrins (Wickham et al., 1993). Penton capsomeres are surrounded by 5 other 
hexon subunits and form the 12 vertices of the icosahedral nucleocapsid. A homotrimeric 
fiber protein is non-covalently bound to each penton capsomere through a conserved N-
terminal FNPVYPY sequence on the fiber protein (Tarassishin et al., 2000). The flexibility 
and the length of the fiber shaft varies greatly, as the fiber is composed of 3 to 23 
pseudorepeats with 15 to 20 residues per repeat depending on the adenovirus type (van 
Raaij et al., 1999). The fiber shaft is also glycosylated, but the function of these 
modifications is unknown (Cauet et al., 2005). The fiber shaft terminates with a globular 
knob domain used to interact with receptors on host cells to facilitate initial virus 
attachment. The fiber protein targets for most HAdV species have yet to be identified, but 
the fiber protein from HAdV species C interacts with the Coxsackie adenovirus receptor 
(CAR) (Bewley et al., 1999).  
 
1.1.3 Human Adenovirus Disease and Tropism 
HAdV are ubiquitous in humans and can infect multiple organ systems; however, these 
infections are usually mild, self-limiting, and may cause illnesses including pharyngitis, 
gastroenteritis, or conjunctivitis. HAdV infections are more prevalent and may cause more 
severe diseases, such as pneumonia, fulminant hepatitis, and/or encephalitis in children and 
immunocompromised patients (Krilov, 2005; Walls et al., 2003). The type of disease 
caused by this virus is also dependent on the HAdV species; for example, species D  
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Figure 1.1. Cartoon depiction of the adenovirus virus particle. A) Cross-section 
diagram showing the arrangement of the various adenovirus structural proteins. Green 
pentagons depict the penton capsomeres, while the blue polygons depict the hexon 
capsomeres. The genome is depicted with the black line depicted in the shape of an 
asterisk inside of the capsid. Adapted from (Russell, 2009). B) Diagram showing one of 
twenty faces of the icosahedral virus capsid. Pentons are shown as pentagons, hexons are 
shown in hexagons, and various other structural proteins labelled in the legend. Adapted 
from (San Martín, 2012). 
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typically cause conjunctivitis, species E causes respiratory infections, and species F and G 
typically cause gastroenteritis (Table 1.1) (Chang et al., 2008; Sambursky et al., 2007; 
Walls et al., 2003). Some HAdV types have also been associated with severe disease 
outbreaks; for example, HAdV-14 caused a fatal pneumonia outbreak in patients living in 
residential care facilities and recruits in military training centers in the United States in 
2005 (Lewis et al., 2009). HAdV-36 has also been linked to obesity in humans, and this 
virus has been experimentally verified to caused increased adiposity in animal models as 
well (Atkinson et al., 2005; Atkinson, 2007; Dhurandhar et al., 2000).  
 
1.1.4 Human Adenovirus Oncogenesis 
Although adenoviruses are classified as small DNA tumour viruses, HAdV do not cause 
cancer in humans (Green et al., 1980; Mackey et al., 1976). These viruses are, however, 
tumourigenic in some rodent species and can transform primary rodent cells in culture 
(Gallimore, 1972; Trentin et al., 1962). The mechanism of transformation by adenoviruses 
require both the viral E1A and E1B proteins (Sherr & McCormick, 2002; Van den Elsen 
et al., 1983). E1A abrogates the activity of retinoblastoma protein (pRb) and its family 
members p107 and p130, which are repressors of the E2F family of transcription factors 
(Cobrinik, 2005; Frolov & Dyson, 2004). The E2F family of transcription factors is largely 
responsible for controlling cell cycle progression from the G1 to S phase (Dyson, 1998). 
By binding to and displacing pRb and its family members from E2F, E1A effectively helps 
circumvent this cell cycle checkpoint to mediate aberrant cell division (Bagchi et al., 1990; 
Zamanian & La Thangue, 1992). Additionally, E1A blocks the activity of cyclin dependent 
kinase inhibitors p16INK4, p21, and p27kip1 to further promote cell cycle progression 
from the G1 to S phase (Alevizopoulos et al., 1998, 2000; Chattopadhyay et al., 2001; Mal 
et al., 1996). Successful cell transformation cannot be accomplished by E1A alone, as E1A-
mediated effects on the cell also cause stabilization of p53 and subsequent p53-mediated 
cell apoptosis (Lowe & Ruley, 1993). Thus, the E1B-55K/E4ORF6 effects of p53 
inhibition and degradation, discussed in the next section, must also be present for 
successful cell transformation (Cathomen & Weitzman, 2000; Van den Elsen et al., 1983). 
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1.1.5 Human Adenovirus Genome 
The adenovirus nucleocapsid contains a 36-38kb linear double-stranded DNA genome, 
which encodes 34-38 proteins from both the forward and reverse strands (Figure 1.2). A 
55kDa terminal protein (pTP) is covalently linked to each 5’ end of adenovirus genome, 
and function as primers for viral replication (Challberg et al., 1980). The adenovirus 
genome can be categorized into transcription units that are expressed either early, delayed, 
or late into the infection cycle. The late phase of an adenovirus infection is defined by the 
commencement of adenoviral genome replication, which occurs approximately 6 hours 
post infection under ideal conditions in tissue culture systems. Early transcription units 
include E1A, E1B, E2B, E3, and E4; delayed units include E2A, IX, and IVa2; and late 
units consist of the major late unit (L) and U exon (U) (Fessler & Young, 1998; Tollefson 
et al., 2007). These transcriptional units occupy both strands of the adenoviral genome, 
with E1A, E1B, E3, IX, and L on the rightward transcription strand, while E2A, E2B, E4, 
IVa2, and U are on the leftward transcription strand (Figure 1.2). Cellular RNA polymerase 
II (RNAPII) transcribes all the aforementioned regions (Berk, 1986). Additionally, 
depending on the virus type, adenoviruses also encode one or two non-coding virus-
associated RNA (VA RNA); these VA RNAs are approximately 160 nucleotides in length, 
localized to the cytoplasm, transcribed by RNA polymerase III, and function to antagonize 
host antiviral responses by blocking the interferon-induced activation of protein kinase R 
(PKR) (Mathews & Shenk, 1991).  
Adenovirus early genes encode for proteins with a variety of functions including regulation 
of viral gene expression, replication of the viral genome, and repression of host antiviral 
responses. E1A is the first region expressed during an adenovirus infection, and is located 
on the leftmost portion of the genome (Nevins et al., 1979). The E1A protein is the main 
topic of this thesis, and will be discussed in more detail in later sections. Briefly, key 
functions of E1A include driving quiescent cells into cell cycle by inducing the disassembly 
of the E2F1-pRb complex, and transactivation of other adenovirus early genes (Berk, 1986; 
DeCaprio, 2009). In HAdV-5, the E1B region codes for two proteins: E1B-19K and E1B-
55K. E1B-19K and E1B-55K block host cell apoptosis by mimicking the anti-apoptotic B-
cell lymphoma 2 protein (Bcl-2), and by forming a complex with E6ORF6 to facilitate the  
10 
 
  
Figure 1.2. Map of transcripts in the HAdV-5 genome. The HAdV-5 genome is 
approximately 36kb long, as shown by the ruler under the black bar. Arrows depict the 
direction of individual transcripts, with the protein product labelled beside the arrow. The 
transcriptional units are labelled below the individual transcripts. Early and delayed genes 
are in green, while late genes are labelled in blue. Orange transcripts depict the HAdV-5 
VA RNAs. Reference genome was obtained from NCBI, with the RefSeq code 
NC_001405.1. 
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degradation of the p53 tumour suppressor protein respectively (White, 2001). E1B-55K 
also plays a crucial role in the export of viral mRNA from the nucleus of host cells to help 
with viral protein production (Gonzalez & Flint, 2002). The E2B region encodes two 
proteins necessary for adenovirus genome replication: pTP, which is covalently linked to 
each 5’ end of the adenovirus genome to function as primers for viral DNA synthesis, and 
the adenovirus DNA dependent DNA polymerase (Ad Pol), which is used to replicate the 
viral genome (Challberg et al., 1980; Field et al., 1984).  
In species C adenoviruses, the E3 region encodes seven immunomodulatory and cell lysis 
proteins. These proteins include E3-12.5K, E3-6.7K, E3-gp19K, adenovirus death protein 
(ADP, also known as E3-11.6K), receptor internalization and degradation protein α (RIDα, 
also known as E3-10.4K), receptor internalization and degradation (RID) protein β (RIDβ, 
also known as E3-14.5K), and E3-14.7K (Lichtenstein et al., 2004). E3-12.5K was 
discovered in 1992 and is highly conserved between HAdV-2, 3, and 5; however, the 
function of this protein is currently unknown (Hawkins & Wold, 1992). E3-6.7K is a type 
III transmembrane protein that inhibits host cell apoptosis by interacting with the RID 
complex (discussed below), maintaining Ca2+ concentrations in the endoplasmic reticulum 
(ER), and reducing tumour necrosis factor (TNF)-mediated release of arachidonic acid 
(Elsing & Burgert, 1998; Moise et al., 2002). E3-gp19K is a type I transmembrane 
glycoprotein that facilitates adenovirus immune evasion by inhibiting the function of major 
histocompatibility complex class I (MHC I) (Burgert et al., 1987; Wold et al., 1985). 
Immune evasion by E3-gp19K is achieved through two known mechanisms that result in 
delayed MHC I maturation: retaining MHC I in the ER and inhibiting the function of 
tapasin, which is a protein that facilitates MHC I peptide loading (Bennett et al., 1999; 
Burgert et al., 1987). E3-11.6K, or ADP, is unique in that although the gene is located 
within an early transcription unit, the protein is produced predominantly during the late 
stages of infection (Tollefson et al., 1992). Like E3-6.7K, ADP is also a type III membrane 
protein (Tollefson et al., 1996). ADP facilitates lysis of adenovirus-infected cells and 
subsequent release of virus particles (Tollefson et al., 1996). RIDα and RIDβ form the RID 
complex, which functions to block apoptosis of the host cell by downregulating 
proapoptotic cell surface receptors such as Fas, TNF-related apoptosis-inducing ligand 
receptor 1 and 2 (TRAILR1 and TRAILR2) and TNF receptor 1 (TNFR1) through receptor 
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internalization and subsequent lysosomal degradation (Benedict et al., 2001; Elsing & 
Burgert, 1998; Friedman & Horwitz, 2002). The downregulation of TRAILR1 and 
TRAILR2 also require an interaction between E3-6.7K and the RID complex. Finally, E3-
14.7K is nonamer that antagonizes TNF-induced apoptosis (Gooding et al., 1988, 1990; 
Kim & Foster, 2002). The mechanism behind the antagonism of TNF-induced apoptosis is 
unknown, but may be related to the interaction between E3-14.7K and the 14.7K-
interacting protein (FIP) family of proteins (Li et al., 1999, 1997).  
The E4 transcriptional unit is located on the right end of the adenovirus genome (Figure 
1.2). In species C adenoviruses, the E4 transcriptional unit encodes several proteins named 
after the order of open reading frames (ORF) from which they originate: E4ORF1 through 
E4ORF4, E4ORF6, and E4ORF6/7 (Täuber & Dobner, 2001). E4ORF1 assists in 
increasing viral replication by dysregulating host cell metabolism and replication through 
several mechanisms. Firstly, E4ORF1, in a E4ORF4-dependent mechanism, activates the 
mechanistic target of rapamycin (mTOR) pathway by activating phosphatidylinositol 3-
kinase (PI3K) (Frese et al., 2003; O’Shea et al., 2005). E4ORF1 also changes host cell 
metabolism in a MYC-dependent mechanism by promoting glycolysis and shunting the 
resulting metabolites to nucleotide biosynthesis pathways (Thai et al., 2014). Interestingly, 
E4ORF1 also plays a role in obesity caused by HAdV-36 infections (Sohrab et al., 2017). 
E4ORF2 is localized to the cytoplasm, but the function of the protein is not known (Dix & 
Leppard, 1995; Thomas et al., 2001). E4ORF3 is involved in the reorganization of 
promyelocytic leukemia (PML) oncogenic domains and inactivation of p53 by inducing 
heterochromatin formation at p53 target promoters (Evans & Hearing, 2003; Soria et al., 
2010). The mechanism of p53 inactivation by E4ORF3 is separate and independent from 
that of E1B (Soria et al., 2010). E4ORF4 inhibits the host DNA damage response (DDR) 
in several ways. With its cellular binding partner protein phosphatase 2 (PP2A), E4ORF4 
reduces phosphorylation of substrates of the phosphatidylinositol 3-kinase-related kinase 
(PIKK) family including ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related 
protein (ATR), resulting in inhibition of various DDR pathways (Brestovitsky et al., 2016). 
E4ORF4 is also able to mislocalize various sensor complexes required to activate ATM 
and ATR, thus preventing downstream DDR signaling (Carson et al., 2009). E4ORF6 is 
yet another adenovirus protein that blocks p53 activity via one of two mechanisms: 
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E4ORF6 by itself can inhibit the interaction between p53 and its transcriptional coactivator, 
TAFII31; or as discussed previously, E4ORF6 forms a complex with E1B-55K to 
ubiquitinate p53, leading to p53 degradation (Dobner et al., 1996; Lu & Levine, 1995; 
Querido et al., 2001). Having so many distinct and redundant avenues of attacking the 
“guardian of the genome” truly illustrates the importance of dismantling the p53 pathway 
in a successful and productive adenovirus infection. The E4ORF6/E1B-55K complex is 
involved in many other processes as well, including viral DNA replication, nuclear export 
of late viral mRNA, and inactivation of DDR (Bridge & Ketner, 1990; Gonzalez & Flint, 
2002; Stracker et al., 2002). Lastly, E4ORF6/7 is a protein that is encoded by DNA from 
both ORFs 6 and 7. This protein forms a complex with the E2F transcription factor, recruits 
it to the E2 early promotor, and induces transactivation of E2 genes (Marton et al., 1990; 
Obert et al., 1994). 
The adenovirus delayed transcription units include E2A, IX, and IVa2. E2A encodes a 
DNA binding protein (DNABP) involved in viral DNA replication (Lindenbaum et al., 
1986). This protein binds to single stranded DNA and stimulates Ad Pol to commence 
DNA synthesis (Lindenbaum et al., 1986). The IX transcription unit encodes pIX, a minor 
“cement” protein present on the exterior surface of the adenovirus capsid, used to link other 
structural proteins together and with the viral core (Liu et al., 2010; Reddy et al., 2010). 
Lastly, IVa2 encodes pIVa2, which is a viral packaging protein that functions as an 
ATPase; pIVa2 forms a complex with other late proteins and the E2A DNABP to facilitate 
loading of the adenovirus genome into an assembled capsid (Ahi et al., 2013; Christensen 
et al., 2008; Ostapchuk & Hearing, 2008).  
Adenovirus late proteins are encoded by the major late transcription unit and the U exon. 
The major late transcription unit is further divided into L1-L5 transcription units. The U 
exon protein (UXP) encoded by the U exon is 24kDa in size, localized to the nucleus and 
viral replication centers, and may be involved in adenovirus DNA replication (Tollefson et 
al., 2007). Proteins encoded by the major late transcriptional unit function mostly as 
adenovirus structural proteins or proteins involved in the viral packaging process (Table 
1.2). Notably, the penton subunit, hexon subunit, and fiber are encoded on L2, L3, and L5  
15 
 
Table 1.2. Proteins encoded by the major late transcription unit. Table showing 
details about the proteins encoded in the L1-L5 transcription units, presence in empty or 
mature capsids, location, and function(s). Adapted from (Ahi & Mittal, 2016), while 
information about L4-100K is adapted from (Cepko & Sharp, 1982). 
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respectively. The other adenovirus late proteins are reviewed extensively by Ahi and Mittal 
(Ahi & Mittal, 2016). 
 
1.1.6 Human Adenovirus E1A Structure 
E1A is the first protein expressed after cell entry, and is tasked with changing the cellular 
landscape to become more conductive for viral replication (Nevins et al., 1979). This 
complex protein is organized into four regions: conserved region (CR) 1, CR2, CR3, and 
CR4. The E1A CR are segments of the protein that share sequence similarity between 
different HAdV types (Figure 1.3) (Avvakumov et al., 2002). These regions are largely 
intrinsically disordered except for CR3, which is predicted to form a Cys4 zinc finger, and 
the N-terminus of E1A from most HAdV types, which is predicted to form an α-helix 
(Figure 1.4) (Pelka et al., 2008). E1A is also alternatively spliced to form different protein 
products depending on the infection phase. In HAdV-5, there are 5 major isoforms of E1A: 
289 residues (R), 243R, 217R, 171R, and 55R, which have mRNA sedimentation rates of 
13S, 12S, 11S, 10S, and 9S respectively (Figure 1.4). 13S E1A, referred to as full length 
E1A for the remainder of this thesis, and 12S E1A are most prominent during the earlier 
phases of infection, while the remaining three isoforms are produced later in infection 
(Perricaudet et al., 1979; Stephens & Harlow, 1987). 
 
1.1.7 Human Adenovirus E1A Transactivation of Viral and Host 
Genes 
Being the first protein expressed, E1A is a strong transcriptional activator that starts the 
infection cycle by driving the expression of other early adenovirus genes (Berk et al., 1979; 
Jones & Shenk, 1979). E1A itself is controlled by a constitutively active enhancer (Hearing 
& Shenk, 1983). The regions responsible for transactivation have been mapped to the N-
terminus and CR3 of E1A (Lillie & Green, 1989; Martin et al., 1990). E1A does not directly 
bind DNA and has no enzymatic activity; therefore, E1A relies on protein-protein 
interactions to mediate its effects (Ferguson et al., 1985). E1A targets various host  
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Figure 1.3. Sequence alignment of full length E1A from HAdV-3, 4, 5, 9, 12, 40, and 
52. E1A sequence from representative adenovirus types from species A through G were 
aligned using Clustal Omega. The PXLXP motifs are outlined in red boxes, and the 
conserved regions are labelled below. Residues with high conservation are shown in blue, 
with darker shading indicating higher levels of conservation.   
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Figure 1.4. PONDR graph of the five different E1A isoforms. Predictor of natural 
disordered regions (PONDR) is an online tool used to predict regions of order or disorder 
from the protein primary sequence. VL-XT is a combination of the VL1 predictor and the 
XN and XC predictors (Li et al., 1999; Romero et al., 1997). The PONDR score is 
between 1 and 0, with 1 being the ideal prediction of order and 0 being the idea prediction 
of disorder. The threshold is assigned at 0.5, where a protein is predicted to be disordered 
in the region with a score higher than 0.5. Here, HAdV-5 E1A primary sequence was the 
input. The four conserved regions are labelled in the bar below the PONDR graph. In 
HAdV-5 13S E1A, CR1 spans residues 40-80 (red), CR2 spans residues 121-139 
(yellow), CR3 spans residues 140-188 (green), and CR4 spans residues 240-288 (blue). 
The five protein isoforms of E1A are also shown, with the residue position in reference 
to 13S E1A labelled in white where the alternative splicing of mRNA occurs. 9S E1A 
uses a different reading frame to code for the C-terminal region (shown in purple), 
resulting in a different protein primary sequence compared to the other E1A isoforms. 
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and viral promoters through an intrinsically-disordered promotor targeting subdomain, 
comprising of residues 183-188 in HAdV-5 E1A (Liu & Green, 1994; Webster & Ricciardi, 
1991). This subdomain can be used to bind with various sequence-specific DNA-binding 
transcription factors such as members of the activating transcription factor (ATF) family, 
c-Jun, Sp1, and upstream stimulatory factor (USF) (Liu & Green, 1994). Subsequently, 
E1A stimulates the formation of the pre-initiation complex by recruiting the MED23 
component of the mediator complex and TATA box binding protein (TBP) to the promotor 
region of target genes (Boyer et al., 1999; Cantin et al., 2003; Geisberg et al., 1994; Wang 
& Berk, 2002). The E1A N-terminus plays a similar role in facilitating transactivation by 
binding to various proteins that control transcription including activating protein 2 (AP2), 
thyroid hormone receptor (TR), p400, GCN5, TBP, and p300/CREB binding protein 
(Eckner et al., 1994; Fuchs et al., 2001; Lang & Hearing, 2003; Lipinski et al., 1998; Meng 
et al., 2003; Somasundaram et al., 1996).  
 
1.1.8 Human Adenovirus E1A is a Viral Hub Protein 
E1A directly binds to over 30 host factors to regulate cell cycle control, protein 
localization, and gene expression through disruption of various cell signaling networks 
(Figure 1.5) (Pelka et al., 2008). This capacity to bind with so many other proteins is 
especially impressive given that HAdV-5 E1A is less than 300 amino acids. As such, E1A 
is a hub protein, characterized by its ability to form a large number of interactions through 
short linear interaction motifs (SLiMs) (Nevins et al., 1979). SLiMs are typically 3 to 10 
residues in length and are used by pathogens, including other viruses, to disrupt host cell 
signaling by mediating various protein-protein interactions (Davey et al., 2011; Via et al., 
2015). These motifs are typically present on intrinsically disordered regions of a protein, 
but may also be found on solvent-exposed surfaces of alpha helices (Van Roey et al., 2014). 
Due to their short length, SLiMs typically mediate interactions that are transient or of low 
affinity; therefore, some protein-protein interactions mechanisms require more than one 
SLiM to facilitate stable binding (Van Roey et al., 2014). Due to the simplicity of many of 
these motifs, SLiMs are an avenue for molecular mimicry and are conducive to 
evolutionary plasticity (Neduva & Russell, 2005). Pathogens, especially viruses due to  
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Figure 1.5. E1A protein interaction network. Graphical representation of the E1A 
primary and secondary interactors. Graph was created using Gephi 0.9.1 with data from 
BioGRID build 3.4.144. E1A is shown in the white circle in the center of the diagram. 
Primary interactors are represented as larger circles near the outer region of the diagram, 
and are supported by at least two peer-reviewed publications. The relative sizes of the 
primary interactors are proportional to its number of binding partners. The primary 
interactors are sorted into 11 groups based on sub-networks using Gephi. The secondary 
interactors are represented by smaller circles scattered throughout the diagram and are 
coloured and positioned closely to the E1A primary interactor with which it binds. There 
are 31 primary interactors and 2125 unique secondary interactors represented in this 
diagram. Graph was created by Dr. Joe Mymryk (University of Western Ontario, 
unpublished, 2017). 
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Figure 1.6. Diagram of E1A interaction partners and short linear motifs within 
conserved region 2. Protein sequence of HAdV-5 E1A (residues 108 – 139) is shown. 
The PXLXP, EVIDLT, and LXCXE motifs are matched with their respective binding 
partners along with a brief description of the function of BS69, UBC9, pRB, and STING. 
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their small and rapidly-evolving genomes, frequently exploit these motifs to hijack specific 
regulatory pathways within the host cell to create a favourable environment for pathogen 
survival and propagation (Neduva & Russell, 2005). SLiMs are particularly common in 
HAdV-5 E1A CR2, as the PXLXP, EVIDLT, and LXCXE motifs exist here in tandem 
(Figure 1.6). The PXLXP and EVIDLT motifs are used to interact with BS69 and small 
ubiquitin-like moiety (SUMO) conjugase ubiquitin conjugase 9 (UBC9) respectively, 
while the LXCXE motif is used to interact with both pRb and stimulator of interferon genes 
(STING) (Ansieau & Leutz, 2002; Avvakumov et al., 2004; Lau et al., 2015; Yousef et al., 
2010). 
 
1.2 Human BS69 
1.2.1 Discovery and Structure of BS69 
BS69, also known as ZMYND11, was initially identified in 1995 as an E1A interacting 
protein (Hateboer et al., 1995).  This protein binds directly to E1A CR2 using the PXLXP 
motif, but there is conflicting data in the literature regarding the involvement of CR3 in 
this interaction (Ansieau & Leutz, 2002; Hateboer et al., 1995). BS69 was first described 
as a strong inhibitor of E1A transactivation; however, it was later found that the repressive 
function of BS69 is not limited to just E1A mediated transcriptional activation (Hateboer 
et al., 1995; Masselink & Bernards, 2000). Recently, BS69 has also been found to be 
involved in epigenetic gene regulation (Guo et al., 2014; Wen et al., 2014). BS69 binds 
specifically to histone H3.3 trimethylated at lysine residue 36 (H3.3K36me3) to cause 
localized gene repression (Guo et al., 2014; Wen et al., 2014). 
BS69 has a molecular weight of 69kDa, and the full-length protein is 602 residues in length. 
BS69 is localized to the nucleus, is ubiquitously expressed, and carries out a variety of 
functions associated with gene regulation (Velasco et al., 2006). This protein consists of 4 
previously described domains: plant homeodomain (PHD); bromodomain (BROMO); 
PWWP domain; and Myeloid, Nervy, and deformed epithelial autoregulatory factor 1 
homolog (DEAF-1) (MYND) domain (Figure 1.7, 1.8). There is also a zinc finger between 
the BROMO and PWWP domains, and a coiled-coil structure and a nuclear localization  
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Figure 1.7. Structure of BS69 MYND domain. Diagram of the BS69 domains and 
nuclear localization sequence (NLS) are shown with the residue positions above. The 
sequence of the MYND domain is below, with the cysteine and histidine residues used to 
coordinate one of the two zinc ions bolded, labelled, and coloured based on which zinc 
ion they coordinate. The MYND domain is composed of two antiparallel beta sheets (red 
and yellow) followed by two alpha helices (green and blue). The NMR structure (PDB: 
2HDA) shows the secondary structures colour coordinated with the sequence above, 
along with the two zinc ions are grey spheres, and the residues used to coordinate these 
ions. Adapted from (Harter et al., 2016).  
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Figure 1.8. Structure of the BROMO and PWWP domains of BS69. NMR structure 
(PDB: 4N4I) of the BS69 BROMO (green) and PWWP (red) domains in both globular 
and ribbon models (Wen et al., 2014). The zinc finger (ZnF) between the domains is 
shown in beige, with an expanded view to show the cysteine and histidine residues used 
to coordinate the zinc ion. A histone H3.3K36me3 peptide is shown in blue. The BROMO 
domain is composed of four alpha helices, while the PWWP domain consists of a beta 
barrel followed by an alpha helix. The bottom diagram on the bottom shows the sequence 
of this region in BS69, along with the location of the secondary structures. The residue 
position is shown below the respective domains. NLS = nuclear localization sequence. 
Adapted from (Wen et al., 2014). 
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signal (NLS) between the PWWP and MYND domains (Harter et al., 2016; Wang et al., 
2014). This protein is highly conserved between humans and mice, especially the MYND 
domains, which share 100% sequence identity (Figure 1.9). The BS69 splice variant, bone 
morphogenetic protein (BMP) receptor associated molecule 1 (BRAM1), consists of 12 
unique N-terminal residues and 185 shared C-terminal residues with BS69 (Kurozumi et 
al., 1998). BRAM1 localizes to the cytoplasm and interacts with BMP type IA receptor and 
plays a role in the BMP signaling pathway (Kurozumi et al., 1998). This pathway is 
required for normal functioning of bone tissues, as its perturbation is correlated with 
various bone diseases (Sánchez-Duffhues et al., 2015). 
 
1.2.2 The Domains and Functions of BS69 
The MYND domain of BS69 is 40 residues in length, and contains two zinc ions 
coordinated by seven cysteine residues and one histidine residue (Figure 1.7). This domain 
contains two anti-parallel beta sheets followed by two alpha helices. The MYND domain 
of BS69 primarily functions to mediate protein-protein interactions with binding partners 
such as E1A, Epstein Barr Nuclear Antigen 2 (EBNA2), nuclear receptor co-repressor 1 
(N-CoR), ETS2, B-myb, C-myb, and zinc fingers and homeoboxes (ZHX) 1 (Ansieau & 
Leutz, 2002; Harter et al., 2016; Hateboer et al., 1995; Ladendorff et al., Lipsick, 2001; 
Masselink & Bernards, 2000; Masselink et al, 2001; Ogata-Kawata et al., 2007; Wei et al., 
2003). E1A, EBNA2, and ZHX1 all use the PXLXP motif to interact with the MYND 
domain; additionally, it is interesting to note that N-CoR and ETS2 also contain PXLXP 
motifs in their primary sequence. E1A and EBNA2 both facilitate transcriptional 
activation, and the interaction with the MYND domain of BS69 represses this function 
(Harter et al., 2016; Hateboer et al., 1995). Similarly, BS69 also inhibits transcriptional 
activation of B-myb and C-myb (Ladendorff et al., 2001; Masselink et al., 2001). The 
mechanism for this repression is not well understood, but may involve the recruitment of 
the N-CoR repressor (Masselink & Bernards, 2000). The opposite is also true, where 
expression of E1A and EBNA2 relieves BS69-mediated gene repression (Ansieau & Leutz, 
2002; Masselink & Bernards, 2000). Interestingly, through this interaction, BS69 has also  
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Figure 1.9. Differences in protein sequence between human BS69 and murine BS69. 
Black rectangles represent the various BS69 domains and the NLS, with numbers on the 
corners representing the residue positions. Sequence changes below denote changes in 
protein sequence from human BS69 to murine BS69. 
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been found to stabilize E1A by inhibiting ubiquitin-dependent degradation of E1A (Isobe 
et al., 2006). 
The activity of several other cellular transcription factors is influenced by the versatile 
BS69 protein. ETS1 and ETS2 are signal-dependent transcription factors that promote 
expression of genes downstream of the rat sarcoma (Ras) / mitogen-activated protein 
kinase (MAPK) signaling pathway (Plotnik et al., 2014). Both these transcription factors 
have the PXLXP motif near the N-terminus of their primary sequences, but only ETS2 
binds to BS69 (Plotnik & Hollenhorst, 2017; Wei et al., 2003). As a consequence, BS69 
preferentially inhibits ETS2-mediated transactivation, making ETS2 a transcriptional 
repressor or weaker activator compared to ETS1 (Plotnik & Hollenhorst, 2017; Wei et al., 
2003). Like the interaction pattern seen with ETS2 and ETS1, BS69 is able to bind to ZHX1 
but not ZHX2 despite both proteins having a PXLXP motif (Kawata et al., 2003; Ogata-
Kawata et al., 2007). Thus, the MYND domain of BS69 binds to various proteins using the 
core PXLXP motif, but it is evident that the context of the motif is also important in 
mediating a strong interaction. The C-terminus of BS69 also binds to several chromatin 
remodeling factors such as BRG1, EZH2, and HDAC1; therefore, BS69 may also play a 
role in chromatin remodeling (Guo et al., 2014; Velasco et al., 2006).  
The PHD, BROMO, and PWWP domains are located in tandem near the N-terminus of the 
protein (Figure 1.8). These domains are also used to facilitate protein-protein interactions, 
most notably with histone tails (Guo et al., 2014; Wen et al., 2014). The PHD domain was 
first discovered in 1993 in Arabidopsis thaliana; since then, more than 170 proteins with 
these domains have been identified in the human genome (Liu et al., 2012; Schindler et al., 
1993). PHD fingers are primarily involved in recognizing various acetylated and di- or 
trimethylated histone tails (Bortoluzzi et al., 2017; Li & Li, 2012). Proteins containing a 
BROMO domain are also prevalent, as there are currently 61 identified modules in 42 
proteins in the human genome (Fujisawa & Filippakopoulos, 2017). These domains are 
also involved in epigenetic regulation of gene expression, although they selectively 
recognize acetylated lysine residues on histone tails (Fujisawa & Filippakopoulos, 2017). 
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Lastly, the PWWP domain is named after a conserved Pro-Trp-Trp-Pro motif found in this 
domain. This domain was first discovered in the histone methyltransferase NSD2 in 1998 
(Stec et al., 1998). Since then, the PWWP domain has been found in over 20 proteins in 
the human genome (Qin & Min, 2014). This domain is capable of binding methylated 
lysine residues on histone tails, and interacting directly with DNA (Qin & Min, 2014). In 
the BS69 protein, these three domains fold together to form a functional module, as they 
are all involved in the interaction with H3.3K36me3 (Guo et al., 2014; Wang et al., 2014; 
Wen et al., 2014). From two crystal structures published by two groups, it is evident that 
the PWWP domain is primarily responsible for the binding specificity between BS69 and 
H3.3K36me3 (Figure 1.10) (Wang et al., 2014; Wen et al., 2014). There are five differences 
in the primary sequences between histone H3.3 and histone H3.1/H3.2, and only one 
difference is within the tail region. Histone H3.3 contains a serine residue at position 32, 
while histone H3.1/H3.2 contain alanine residues at this position (Figure 1.10). The serine 
residue in histone H3.3 binds to the interface between the zinc finger and the PWWP 
domain of BS69, and is crucial in the formation of a strong interaction between these two 
proteins; therefore, post-translational modification to this serine residue, such as 
phosphorylation, may play a role in the regulation of this protein-protein interaction (Guo 
et al., 2014; Wen et al., 2014).  
 
1.2.3 BS69 Uses an Epigenetic Mechanism to Downregulate 
Gene Expression 
BS69 downregulates gene expression of genes decorated with H3.3K36me3 through two 
mechanisms: suppression of RNA polymerase elongation and upregulation of intron 
retention (Guo et al., 2014; Wen et al., 2014). Using RNA-seq analysis, Wen et al. noted 
that RNAPII elongation in gene bodies was greater in BS69-depleted cells compared to a 
wildtype control, while the density of RNAPII in respective promoter regions were 
unchanged (Wen et al., 2014). These BS69-depleted cells also have increased elongation 
specific RNAPII levels, denoted by phosphorylation of serine residue at position 2 in the 
unique heptameric YSPTSPS sequence in the C-terminal domain of RNAPII (Ahn et al., 
2004; Wen et al., 2014). Lastly, chromatin immunoprecipitation sequencing (ChIP-seq)  
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Figure 1.10. Interaction between the BROMO and PWWP domains of BS69 with 
H3.3K36me3. NMR structure (PDB: 4N4I) of the BS69 BROMO (green) and PWWP 
(red) domains (Wen et al., 2014). The zinc finger (ZnF) between the domains is shown 
in beige. A histone H3.3K36me3 peptide is shown in blue. The S32 residue is shown 
zoomed in on top, while the bottom panel shows trimethylated K36 residue. Sequence 
alignment of Histone H3.1, H3.2, and H3.3 is shown on the bottom. Residues with high 
conservation are shown in blue, with darker shading indicating higher levels of 
conservation. Adapted from (Wen et al., 2014). 
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showed that BS69 co-localizes with histone H3.3K36me3 on transcriptionally active genes 
(Guo et al., 2014; Wen et al., 2014). Altogether, these results demonstrate that BS69 
negatively regulates RNAPII elongation in genes decorated with histone H3.3K36me3 
(Wen et al., 2014).  
RNA splicing is also regulated by BS69 in genes decorated with the H3.3K36me3 marker 
(Guo et al., 2014). Using Co-immunoprecipitation (Co-IP), Guo et al. showed that 
chromatin-bound BS69 interacts with various components of the spliceosome, which is a 
molecular complex used to mediate RNA splicing, including elongation factor Tu GTP-
binding domain-containing protein 2 (EFTUD2), pre-mRNA processing splicing factor 8 
(PRPF8), U5 small nuclear ribonucleoprotein 200 kDa helicase (SNRNP200), 
serine/arginine-rich splicing factor 1 (SRSF1), and pinin (PNN) (Guo et al., 2014). 
EFTUD2, PRPF8, and SNRNP200 are all components of the U5 spliceosome, while 
SRSF1 and PNN are members of a conserved family of serine and arginine-rich proteins 
also involved in RNA splicing (Guo et al., 2014). Using RNA-seq, the group found that 
BS69-depleted cells exhibited decreased intron retention events compared to wildtype 
cells, and that this observation is dependent on the interaction between BS69 and the U5 
spliceosome component, EFTUD2 (Guo et al., 2014). Furthermore, BS69 is enriched at 
these alternatively spliced genes, and intron retention of these transcripts causes nonsense-
mediated mRNA decay (Guo et al., 2014). In summary, these studies have demonstrated 
two novel mechanisms by which BS69 is able use epigenetic mechanisms to regulate gene 
expression.  
 
1.2.4 Disease Association of BS69 and Histone H3.3 Mutants 
Mutations in either BS69 or histone H3.3 have also been linked to various diseases. 
Mutations in histone H3.3 are correlated with pediatric brain cancers and bone cancers; 
specifically, K27M, G34R/V/W/L, and K36M mutations in the histone tail of histone H3.3 
is associated with glioblastoma multiforme, chondroblastoma, giant-cell tumour of the 
bone, and human papillomavirus-negative head and neck squamous cell carcinoma 
(Behjati et al., 2013; Fontebasso et al., 2014; Papillon-Cavanagh et al., 2017; 
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Schwartzentruber et al., 2012). Interestingly, the K27M mutation decreases methylation of 
the lysine residue 36 in histone H3.3 tails in human embryonic kidney 293 (HEK293) cells 
as well (Chan et al., 2013). Additionally, a consequence of the K36M mutation prevalent 
in giant-cell tumour of the bone is that BS69 can no longer bind to the histone tail (Behjati 
et al., 2013; Wang et al., 2014). Mutations and copy number variations in BS69 have also 
been linked to cognitive / developmental delay and various hematological malignancies; 
however, a mechanistic connection between abrogation of BS69 function and disease has 
not yet been made (Cobben et al., 2014; Coe et al., 2014; DeScipio et al., 2012; Moskowitz 
et al., 2016; Walter et al., 2009; Yang et al., 2010).  
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1.3 Rationale, Hypothesis, and Objectives 
BS69 was first identified in 1995 as an E1A interactor through a pulldown screen 
performed by the Bernards group (Hateboer et al., 1995). The protein was described as an 
inhibitor of transactivation, but the mechanism by which this occurs and the genetic targets 
are unclear. Furthermore, this interaction has also only been studied in the prototypical 
HAdV-5 of species C, and it is uncertain if this interaction is conserved in other adenovirus 
species. The binding surface is also poorly described, making it difficult to construct the 
appropriate E1A mutants required to study this interaction. In 2014, two publications 
showed that BS69 is also a histone reader that specifically targets histone H3.3 
trimethylated at lysine residue 36 (H3.3K36me3) (Guo et al., 2014; Wen et al., 
2014).Therefore, this E1A binding protein may also be involved in epigenetic mechanisms 
of gene regulation. Thus, I set out to characterize this interaction and examine its effects 
on E1A mediated gene transcription. 
Based on the rationale, I hypothesize that the interaction between E1A and BS69 alters 
transcriptional regulation of viral and host genes. To investigate my hypothesis, I have 
formed three objectives: 
 
1. Determine the specific residues of E1A required to bind with BS69 and the 
conservation of this interaction in different human adenovirus species. 
2. Examine the effects of BS69 on E1A mediated transcriptional activation.  
3. Construct a BS69-deficient cell line to study changes in BS69-mediated gene 
expression. 
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2 Materials and Methods 
 
2.1 Generation of Plasmids 
Plasmids 8-15 (Table 2.1) were generated by combining self-annealing oligonucleotides 
and ligating them into the pBAIT (plasmid 1, Table 2.1) backbone vector (Zhang et al., 
2001). Oligonucleotides (Table 2.2) were first diluted to 10 µM and were phosphorylated 
using 10U of polynucleotide kinase (PNK) (New England Biolabs) in T4 DNA ligase 
buffer (New England Biolabs) in a 20µl reaction at 37oC for 1 hour. The kinase was then 
deactivated by incubating the mixture at 65oC for 20 minutes. The phosphorylated self-
annealing oligonucleotide pairs (Table 2.2) were mixed together and incubated at a final 
concentration of 0.5µM each primer in 100µl of ddH2O at 98oC for 2 minutes, then cooled 
gradually to 25oC over 45 minutes using a thermocycler (SimpliAmp from Applied 
Biosystems). 2µg of the pBAIT backbone vector was then digested using EcoRI-high 
fidelity (HF) and SalI-HF (New England Biolabs) at 37oC for 1 hour in CutSmart buffer 
(New England Biolabs). After digestion, the DNA was resolved on an agarose gel and the 
bands of interest were cut and processed using EZ-10 Spin Columns (BioBasic) according 
to the manufacturer’s protocol. The double-stranded oligonucleotides were then diluted 
1:100 in ddH2O before being ligated into the corresponding sites of pBAIT using the Quick 
Ligation Kit (New England Biolabs) according to the manufacturer’s protocol.  
Plasmids (16-30) were generated using overlap extension (Ho et al., 1989). Polymerase 
chain reaction (PCR) amplification of E1A mutants were completed using Phusion 
Polymerase (Thermo Fisher) according to the manufacturer’s protocol. The first round of 
PCR was completed using 10µM each of the matching forward and reverse primers (Table 
2.3), and 250ng template DNA in a 50µl reaction. The reaction underwent 35 cycles with 
the annealing and extension steps completed at 60oC for 30 seconds and 72oC for 15 
seconds respectively. The PCR mix was then incubated with 1µl DpnI (New England 
Biolabs) at 37oC for 1 hour to digest the plasmid template before the PCR products were 
purified using the GeneJET PCR Purification Kit (Thermo Fisher) according to the 
manufacturer’s protocol. Matching pairs  
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Table 2.1. List of Plasmids Used in this Study 
# Name Backbone  Description / Insert 
1 pBAIT pBAIT 
Bait vector used for yeast two-hybrid 
assays. Contains N-terminal LexA 
DBD to the MCS, AmpR, LEU2. 
2 pBAIT HAdV-3 E1A CR2 pBAIT aa 85-150 of HAdV-3 E1A 
3 pBAIT HAdV-4 E1A CR2 pBAIT aa 91-145 of HAdV-4 E1A 
4 pBAIT HAdV-5 E1A CR2 pBAIT aa 93-139 of HAdV-5 E1A 
5 pBAIT HAdV-9 E1A CR2 pBAIT aa 84-138 of HAdV-9 E1A 
6 pBAIT HAdV-12 E1A CR2 pBAIT aa 84-146 of HAdV-12 E1A 
7 pBAIT HAdV-40 E1A CR2 pBAIT aa 78-142 of HAdV-40 E1A 
8 pBAIT E1A T1 pBAIT aa 111-120 of HAdV-5 E1A 
9 pBAIT E1A T2 pBAIT aa 112-120 of HAdV-5 E1A 
10 pBAIT E1A T3 pBAIT aa 111-119 of HAdV-5 E1A 
11 pBAIT E1A T4 pBAIT aa 112-119 of HAdV-5 E1A 
12 pBAIT E1A T5 pBAIT aa 112-118 of HAdV-5 E1A 
13 pBAIT E1A T6 pBAIT aa 113-118 of HAdV-5 E1A 
14 pBAIT E1A T7 pBAIT aa 112-117 of HAdV-5 E1A 
15 pBAIT E1A T8 pBAIT aa 113-117 of HAdV-5 E1A 
16 pBAIT E1A M1 pBAIT S111A CR2 of HAdV-5 E1A 
17 pBAIT E1A M2 pBAIT M112A CR2 of HAdV-5 E1A 
18 pBAIT E1A M3 pBAIT P113A CR2 of HAdV-5 E1A 
19 pBAIT E1A M4 pBAIT N114A CR2 of HAdV-5 E1A 
20 pBAIT E1A M5 pBAIT L115A CR2 of HAdV-5 E1A 
21 pBAIT E1A M6 pBAIT V116A CR2 of HAdV-5 E1A 
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Table 2.1. List of Plasmids Used in this Study (Continued) 
22 pBAIT E1A M7 pBAIT P117A CR2 of HAdV-5 E1A 
23 pBAIT E1A M8 pBAIT E118A CR2 of HAdV-5 E1A 
24 pBAIT E1A M9 pBAIT V119A CR2 of HAdV-5 E1A 
25 pBAIT E1A M10 pBAIT I120A CR2 of HAdV-5 E1A 
26 pBAIT E1A M11 pBAIT P113A L115A P117A CR2 of HAdV-5 E1A 
27 pBAIT E1A M12 pBAIT M112I L115A CR2 of HAdV-5 E1A 
28 pBAIT E1A M13 pBAIT P113A L115A CR2 of HAdV-5 E1A 
29 pBAIT E1A M14 pBAIT M112I L115A CR2 of HAdV-5 E1A 
30 pBAIT E1A M15 pBAIT L115A P117A CR2 of HAdV-5 E1A 
31 pJG4-5+ pJG4-5+ 
Prey vector used for yeast two-hybrid 
assays. Contains N-terminal B42 
activation domain to MCS, HA Tag, 
AmpR, TRP1. GAL1 promoter.  
32 pJG4-5+ BS69 MYND pJG4-5+ BS69 MYND domain aa 427-602 
33 pSH18-34 pSH18-34 
Yeast two-hybrid reporter plasmid. 
Contains 8x LexA binding sites 
upstream  
34 pEGFP pEGFP Mammalian plasmid to express N-terminal EGFP to the MCS, KanR. 
35 pEGFP 13S E1A pEGFP Full length HAdV-5 E1A 
36 pEGFP CR2 E1A pEGFP aa 93-139 of HAdV-5 E1A 
37 pEGFP CR2-CR3 E1A pEGFP 
aa 93-204 of HAdV-5 E1A (insert 
generated by PCR from plasmid 35) 
38 pcDNA3 HA pcDNA3 HA 
Mammalian plasmid to express N-
terminal HA tag to the MCS, AmpR. 
39 pcDNA3 HA BS69 Full Length 
pcDNA3 
HA 
BS69 Full Length aa 46-602 (insert 
generated by PCR from plasmid 53) 
40 pcDNA3 HA BS69 MYND 
pcDNA3 
HA BS69 MYND domain aa 427-602  
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Table 2.1. List of Plasmids Used in this Study (Continued) 
41 pcDNA3 HA BS69 No MYND 
pcDNA3 
HA 
BS69 No MYND domain aa 46-426 
(insert generated by PCR from 
plasmid 53). 
42 pET28a BS69 pET28a 
Protein purification plasmid. Contains 
N-terminal 6x His tag, thrombin 
cleavage site, BS69 MYND domain 
aa 427-602, KanR). 
43 pGEX-4T1 BS69 Full Length pGEX-4T1 
Protein purification plasmid. Contains 
N-terminal GST tag, thrombin 
cleavage site, BS69 Full Length aa 
46-602, AmpR. 
44 pGEX-4T1 BS69 MYND pGEX-4T1 BS69 MYND domain aa 427-602 
45 pGEX-4T1 Rb pGEX-4T1 Rb small pocket aa 385-773 
46 pGEX-4T1 UBC9 pGEX-4T1 UBC9 full length aa 1-158 
47 pM pM 
Mammalian plasmid to express N-
terminal GAL4 DBD (aa 1-147) to the 
MCS, AmpR. 
48 pGL2-(UAS)6-Luc 
pGL2-
(UAS)6-
Luc 
Mammalian luciferase reporter 
plasmid. Contains 6x GAL4 binding 
sites upstream of the luciferase 
reporter gene. 
49 pM 13S Ad5 E1A pM Full length HAdV-5 E1A 
50 pM 13S Ad12 E1A pM Full length HAdV-12 E1A 
51 pM 13S Ad40 E1A pM Full length HAdV-40 E1A 
52 pM 13S E1A L115A pM L115A full length HAdV-5 E1A  
53 pRc/CMV BS69 pRc/CMV Mammalian expression vector containing full length BS69, AmpR.  
54 pSV-β-galactosidase pSV 
Internal control vector for luciferase 
assays. SV40 promoter and 
enhancer upstream of the lacZ gene. 
AmpR 
 
Note: AmpR = ampicillin resistance gene, KanR = kanamycin resistance gene, 
MCS = multiple cloning site, UAS = upstream activation sequence, DBD = DNA 
binding domain 
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Table 2.2. List of Self-Annealing Oligonucleotides Used in this Study 
Construct Oligonucleotide Sequences (5’ à 3’) 
E1A T1 
AATTCTCTGGTGGTTCTATGCCAAACCTTGTACCGGAGGTGATCTA
AG (F) 
TCGACTTAGATCACCTCCGGTACAAGGTTTGGCATAGAACCACCAG
AG (R)  
E1A T2 
AATTCTCTGGTGGTATGCCAAATTTAGTTCCAGAAGTTATCTAAG (F) 
TCGACTTAGATAACTTCTGGAACTAAATTTGGCATACCACCAGAG 
(R)  
E1A T3 
AATTCTCTGGTGGTTCTATGCCAAATTTAGTTCCAGAAGTTTAAG (F) 
TCGACTTAAACTTCTGGAACTAAATTTGGCATAGAACCACCAGAG 
(R) 
E1A T4 AATTCTCTGGTGGTATGCCAAATTTAGTTCCAGAAGTTTAAG (F) TCGACTTAAACTTCTGGAACTAAATTTGGCATACCACCAGAG (R) 
E1A T5 AATTCTCTGGTGGTATGCCAAATTTAGTTCCAGAATAAG (F) TCGACTTATTCTGGAACTAAATTTGGCATACCACCAGAG (R) 
E1A T6 AATTCTCTGGTGGTCCAAATTTAGTTCCAGAATAAG (F) TCGACTTATTCTGGAACTAAATTTGGACCACCAGAG (R) 
E1A T7 AATTCTCTGGTGGTATGCCAAATTTAGTTCCATAAG (F) TCGACTTATGGAACTAAATTTGGCATACCACCAGAG (R) 
E1A T8 AATTCTCTGGTGGTCCAAATTTAGTTCCATAAG (F) TCGACTTATGGAACTAAATTTGGACCACCAGAG (R) 
 
Note: (F) = Forward primer, (R) = Reverse primer 
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Table 2.3. List of Oligonucleotides used for PCR Cloning in this Study 
Construct Oligonucleotide Sequences (5’ à 3’) Template 
E1A End GCGGAATTCCCTCACCTTTCCCGGCAG (F) CGTGTCGACTTAACCCTCTTCATCCTCGTCGTCAC (R) N/A 
E1A M1 GGGTCCGGTTGCTATGCCAAAC (F) GTTTGGCATAGCAACCGGACCC (R) 
pEGFP 
13S E1A  
E1A M2 GTCCGGTTTCTGCGCCAAACCTTG (F) CAAGGTTTGGCGCAGAAACCGGAC (R) 
pEGFP 
13S E1A 
E1A M3 TCCGGTTTCTATGGCAAACCTTGTACC (F) GGTACAAGGTTTGCCATAGAAACCGGA (R) 
pEGFP 
13S E1A 
E1A M4 TTTCTATGCCAGCCCTTGTACCGGAGG (F) CCTCCGGTACAAGGGCTGGCATAGAAA (R) 
pEGFP 
13S E1A 
E1A M5 GGTTTCTATGCCAAACGCTGTACC (F) GGTACAGCGTTTGGCATAGAAACC (R) 
pEGFP 
13S E1A 
E1A M6 CCAAACCTTGCTCCGGAGGTG (F) CACCTCCGGAGCAAGGTTTGG (R) 
pEGFP 
13S E1A 
E1A M7 CAAACCTTGTAGCGGAGGTGATCGATC (F) GATCGATCACCTCCGCTACAAGGTTTG (R) 
pEGFP 
13S E1A 
E1A M8 CCTTGTACCGGCGGTGATCGATC (F) GATCGATCACCGCCGGTACAAGG (R) 
pEGFP 
13S E1A 
E1A M9 CTTGTACCGGAGGCGATCGATCTTACC (F) GGTAAGATCGATCGCCTCCGGTACAAG (R) 
pEGFP 
13S E1A 
E1A M10 CCGGAGGTGGCAGATCTTACCTGC (F) GCAGGTAAGATCTGCCACCTCCGG (R) 
pEGFP 
13S E1A 
E1A M11 TATGGCAAACGCTGTAGCGGAG (F) CTCCGCTACAGCGTTTGCCATA (R) 
pEGFP 
13S E1A 
E1A M12 TCCGGTTTCTATCCCAAACGCTGTAC (F) GTACAGCGTTTGGGATAGAAACCGGA (R) 
pEGFP 
13S E1A 
E1A M13 TCCGGTTTCTATGGCAAACGCTGTAC (F) GTACAGCGTTTGCCATAGAAACCGGA (R) 
pEGFP 
13S E1A 
E1A M14 GTCCGGTTTCTATCGCAAACGCTGTAC (F) GTACAGCGTTTGCGATAGAAACCGGAC (R) 
pEGFP 
13S E1A 
E1A M15 AACGCTGTAGCGGAGGTGATCG (F) CGATCACCTCCGCTACAGCGTT (R) 
pEGFP 
13S E1A 
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Table 2.3. List of Oligonucleotides used for PCR Cloning in this Study (Continued) 
pEGFP 
CR2-CR3 
E1A 
GCGGAATTCCCTCACCTTTCCCGGCAG (F) 
ATTGTCGACTTAGGTAGGTCTTGCAGGCTC (R) 
pEGFP 
13S E1A 
pcDNA3 
HA BS69 
Full Length 
AATGAATTCATGCACCCTAAAGAGACCACCCGT (F) 
ATTCTCGAGTCATCTTTTCCGCGCGCAGGT (R) 
pRc/CMV 
BS69 
pcDNA3 
HA BS69 
No MYND 
AATGAATTCATGCACCCTAAAGAGACCACCCGT (F) 
AATCTCGAGTCACGTGGGTATTTCCTGGCTAGAACTT
ACTGCT (R) 
pRc/CMV 
BS69 
 
Note: (F) = Forward primer, (R) = Reverse primer 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
of purified PCR products were then combined and underwent a second round of PCR to 
generate the full length insert using Phusion Polymerase (Thermo Fisher) according to the 
manufacturer’s protocol. 30ng of each PCR product was used in a 45µl reaction. This 
reaction underwent 15 cycles with the annealing and extension steps completed at 60oC for 
45 seconds and 72oC for 60 seconds respectively. End primers were then added to the PCR 
mixture to a final concentration of 10µM each, and the reaction underwent 15 more cycles 
with the annealing and extension steps completed at 55oC and 72oC respectively for 60 
seconds at each step. The PCR mixture was purified again using the GeneJET PCR 
Purification Kit (Thermo Fisher) according to the manufacturer’s protocol. The purified 
insert and 2µg of the pBAIT backbone vector were then digested using EcoRI-HF and SalI-
HF (New England Biolabs) at 37oC for 1 hour in CutSmart buffer (New England Biolabs). 
After digestion, the purified insert and backbone vector were resolved on an agarose gel. 
The bands of interest were then cut and processed using EZ-10 Spin Columns (BioBasic) 
according to the manufacturer’s protocol. The inserts were ligated into the corresponding 
sites of pBAIT using the Quick Ligation Kit (New England Biolabs) according to the 
manufacturer’s protocol. 
Plasmids (16-30) were generated using overlap extension (Ho et al., 1989). Polymerase 
chain reaction (PCR) amplification of E1A mutants was completed using Phusion 
Polymerase (Thermo Fisher) according to the manufacturer’s protocol. The first round of 
PCR was completed using 10µM each of the matching forward and reverse primers (Table 
2.3), and 250ng template DNA in a 50µl reaction. The reaction underwent 35 cycles with 
the annealing and extension steps completed at 60oC for 30 seconds and 72oC for 15 
seconds respectively. The PCR mix was then incubated with 1µl DpnI (New England 
Biolabs) at 37oC for 1 hour to digest the plasmid template before the PCR products were 
purified using the GeneJET PCR Purification Kit (Thermo Fisher) according to the 
manufacturer’s protocol. Matching pairs of purified PCR products were then combined and 
underwent a second round of PCR to generate the full length insert using Phusion 
Polymerase (Thermo Fisher) according to the manufacturer’s protocol. 30ng of each PCR 
product was used in a 45µl reaction. This reaction underwent 15 cycles with the annealing 
and extension steps completed at 60oC for 45 seconds and 72oC for 60 seconds respectively. 
End primers were then added to the PCR mixture to a final concentration of 10µM each, 
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and the reaction underwent 15 more cycles with the annealing and extension steps 
completed at 55oC and 72oC respectively for 60 seconds at each step. The PCR mixture 
was purified again using the GeneJET PCR Purification Kit (Thermo Fisher) according to 
the manufacturer’s protocol. The purified insert and 2µg of the pBAIT backbone vector 
were then digested using EcoRI-HF and SalI-HF (New England Biolabs) at 37oC for 1 hour 
in CutSmart buffer (New England Biolabs). After digestion, the purified insert and 
backbone vector were resolved on an agarose gel. The bands of interest were then cut and 
processed using EZ-10 Spin Columns (BioBasic) according to the manufacturer’s protocol. 
The inserts were ligated into the corresponding sites of pBAIT using the Quick Ligation 
Kit (New England Biolabs) according to the manufacturer’s protocol. 
Plasmids (37, 39, 41) were generated using PCR to amplify the gene of interest from a 
plasmid template (Table 2.1). PCR amplification of the BS69 and E1A inserts using 
matching forward and reverse primers (Table 2.3) were completed using Phusion 
Polymerase (Thermo Fisher) according to the manufacturer’s protocol. The BS69 template 
was provided by Dr. Rene Bernards (Utrecht University). PCR was completed using 10µM 
of forward and reverse primers each, and 250ng template DNA in a 50µl reaction. The 
reaction underwent 35 cycles with the annealing and extension steps completed at 60oC for 
30 seconds and 72oC for 15 seconds respectively. The PCR mix was purified using the 
GeneJET PCR Purification Kit (Thermo Fisher) according to the manufacturer’s protocol. 
The purified insert and the pcDNA3 HA or pEGFP backbone vector were then digested 
using a combination of EcoRI-HF and SalI-HF or XhoI (New England Biolabs) (Table 2.3) 
at 37oC for 1 hour in CutSmart buffer (New England Biolabs). After digestion, the DNA 
was resolved on an agarose gel and the bands of interest were then cut and processed using 
EZ-10 Spin Columns (BioBasic) according to the manufacturer’s protocol. The inserts 
were ligated into the corresponding sites of pcDNA3 HA or pEGFP using the Quick 
Ligation Kit (New England Biolabs) according to the manufacturer’s protocol. 
Plasmids 1-7, 20, 31-34 35-36, 38, 44-46, and 49-51 (Table 2.1) were previously generated 
by other members of the lab. Plasmids 1, 38 were generated by Dr. Joe Mymryk (University 
of Western Ontario); 2-7, 35 by Jennifer Curran; 20, 46 by Dr. Greg Fonseca (University 
of California San Diego); 31, 49 by Dr. Nik Avvakumov (Laval University); 32, 36 by Dr. 
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Ahmed Yousef (Masdar Institute of Science and Technology); 33 by Dr. Michael Shuen 
(University of Western Ontario); 34 by Stephanie Derbyshire; 44 by Cason King; 45 by 
Dr. Fred Dick (University of Western Ontario); and 50-51 by Dr. Jailal Ablack (University 
of California San Diego). Plasmids 40, 42, 43, and 52 were generated by subcloning 
previously generated inserts into a new backbone using the same restriction sites. Plasmid 
47 was obtained from Clontech, 48 from Dr. Joe Torchia (University of Western Ontario) 
and 53 from Dr. Rene Bernards (Utrecht University). 
All plasmids were transformed into competent DH5a Escherichia coli grown in lysogeny 
broth (LB) (10g/L tryptone, 5g/L yeast extract, and 86mM NaCl; all from Bioshop) 
supplemented with ampicillin (Amp) (50µg/ml, BioShop) or kanamycin (20µg/ml, 
BioShop) as required (Chung et al., 1989). Small-scale preparations of plasmid DNA used 
for cloning and yeast transformations were generated using the PureLink Quick Plasmid 
Miniprep Kit (Invitrogen), while large-scale preparations of plasmid DNA used for 
transfections were generated using the PureLink HiPure Plasmid Filter Midiprep Kit 
(Invitrogen) according to the manufacturer’s protocol.  
 
2.2 Yeast Culture and Transformation 
Yeast culture and transformation were completed as previously described (Adams et al., 
1997; Gietz et al., 1995). W303-1A (MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 
his3-11,15) yeast were streaked from frozen stock onto yeast extract peptone (YEP) plates 
(yeast extract 10g/L, peptone 20g/L, 2% glucose, and 2% agar; all from Bioshop). The 
plates were incubated in 30oC for 72 hours before colonies were picked for overnight 
growth with shaking at 30oC in liquid YEP culture media (yeast extract 10g/L, peptone 
20g/L, and 2% glucose; all from Bioshop). The liquid yeast culture was then diluted 1:2 in 
liquid YEP culture media and grown until the optical density at 600nm (OD600) reached 
1.0. The yeast cultures were then aliquoted into 1.5ml fractions and pelleted in a centrifuge 
for 15 seconds at room temperature. The pellets were resuspended in 1ml of 100mM 
lithium acetate (LiAc) (BioShop) and incubated for 5 minutes at 30oC. After the incubation, 
the yeast mixture was pelleted in a centrifuge and resuspended in a 351µl transformation 
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mixture (34% polyethylene glycol 3350 (PEG), 100mM LiAc, and 0.14mg/ml salmon 
sperm DNA (SS-DNA); SS-DNA is from Sigma, all other components are from BioShop) 
with 200ng of each bait (plasmids 2-30, Table 2.1), prey (plasmids 31-32, Table 2.1) and 
reporter (plasmid 33, Table 2.1) plasmids. The suspension was then incubated for 30 
minutes at 42oC. Finally, the mixture was pelleted in a centrifuge, resuspended in 100µl 
ddH2O, and plated onto synthetic drop-out plates (1.4g/L Y2001 Yeast Synthetic Drop-out 
Medium Supplements, 58µM L-tryptophan, 70mM D-glucose, 2% agar; Y2001 
supplements are from Sigma, all other components are from Bioshop). The plates were 
then incubated in 30oC for 72 hours before being picked for inoculation into 5ml of 
synthetic drop-out liquid media (1.4g/L Y2001 Yeast Synthetic Drop-out Medium 
Supplements, 58µM L-tryptophan, 70mM D-galactose; Y2001 supplements are from 
Sigma, all other components are from Bioshop) for overnight growth at 30oC in a rotating 
drum. Galactose was used as the carbon source in place of glucose to induce expression of 
the GAL1 driven pJG4-5+ vector. The cultures were then used for yeast two-hybrid assays 
(Section 2.3) or protein extraction for western blot analysis (Section 2.4). Centrifugation 
was carried out at 15000 relative centrifugal force (RCF) unless otherwise stated. 
 
2.3 Yeast Two-Hybrid Assays 
Yeast two-hybrid assays were completed as previously described (Adams et al, 1997). 
1.5ml of the overnight yeast cultures were pelleted in a centrifuge for 15 seconds at room 
temperature, washed, and resuspended in 1ml Z-Buffer (60mM Na2HPO4, 40mM 
Na2H2PO4, 10mM KCl, 1mM MgSO4, and 50mM β-mercaptoethanol (BME); all from 
Bioshop, pH 7.0). The suspensions were then concentrated or diluted in Z-buffer until the 
OD600 was between 0.2 and 0.8. Then, 500µl of the suspensions were transferred to another 
microfuge tube containing 500µl Z-Buffer. Next, 20µl of 0.1% sodium dodecyl sulfate 
(SDS) (BioShop) and chloroform (Fisher Scientific) were added to each tube before being 
vortexed vigorously for 30 seconds. The samples were incubated in 30oC for 15 minutes, 
then 200µl ortho-nitrophenyl-β-galactoside (ONPG) (4mg/ml, from Bioshop, in Z-Buffer) 
was added to each tube. The samples were then vortexed vigorously for 30 seconds before 
being incubated in 30oC. To terminate the reaction, 0.5ml of 1M Na2CO3 (Bioshop) was 
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added to the samples after they turned pale yellow. The duration between the addition of 
ONPG and termination of the reaction was noted to calculate b-galactosidase activity. The 
samples were then centrifuged for 10 minutes to remove cellular debris and the optical 
density at 420nm (OD420) was measured. 
The equation to determine the b-galactosidase activity is as follows: 
 
Activity	in	Miller	Units = 𝑂𝐷234𝑂𝐷544	×	𝑣𝑜𝑙𝑢𝑚𝑒	×	𝑡𝑖𝑚𝑒		×	1000 
 
Where volume is the amount in ml of yeast suspension transferred to the new tube 
containing Z-buffer after the OD600 was measured; OD420 was measured after the addition 
of Na2CO3 and time is the period in minutes between the addition of ONPG and Na2CO3.  
 
2.4 Yeast Protein Extraction of Western Blot Analysis 
Yeast protein extractions were prepared as previously described (von der Haar, 2007). 
First, 1ml of liquid overnight yeast cultures were pelleted in a centrifuge for 15 seconds at 
room temperature, washed in ddH2O, and resuspended in 200µl yeast lysis buffer (0.1M 
NaOH, 0.05M EDTA, 2% SDS, and 2% BME; all from BioShop). The suspensions were 
then incubated in 90oC for 10 minutes. Next, 5µl of 4M acetic acid (BioShop) was added 
to the suspensions before the samples were briefly vortexed. The samples were then 
incubated again in 90oC for 10 minutes. Finally, 50µl of yeast loading buffer (0.25M Tris-
HCl pH 6.8, 50% glycerol, and 0.05% bromophenolblue, Tris-HCl and glycerol are from 
BioShop, bromophenolblue is from Sigma) was added to the suspensions before being 
vortexed and loaded into polyacrylamide gels for western blot analysis. 
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2.5 Cell Culture and Transfection 
HT1080 human fibrosarcoma cells were used for the co-IP and luciferase experiments, 
while A549 lung epithelial carcinoma cells and IMR-90 primary lung fibroblast cells were 
used for the silencing RNA (siRNA) knockdown experiments. HT1080 cells were chosen 
because they transfect with high efficiency, while A549 and IMR-90 cells were used for 
their susceptibility to adenovirus infection for future experiments. All cells were cultured 
in Dulbecco’s modified eagle medium (DMEM) (Multicell) supplemented with 10% fetal 
bovine serum (FBS) (Multicell), 100IU/ml penicillin (Multicell), and 100µg/ml 
streptomycin (Multicell). All cells were grown in a 37oC incubator with 5% CO2.  
For co-IP experiments, HT1080 cells were grown on 10cm cell culture plates (Sarstedt).  
2.2x106 HT1080 cells were seeded per 10cm plate and transfected 24 hours later with 4µg 
each of plasmids containing HA-tagged BS69 (plasmid 39, Table 2.1), and a green 
fluorescent protein (GFP)-tagged E1A construct (plasmids 35-37, Table 2.1) or GFP alone 
(plasmid 34, Table 2.1). Transfections were carried out using X-tremeGene HP DNA 
Transfection Reagent (Roche) according to the manufacturer’s protocol. 
For luciferase assays and transfections to verify antibody specificity, HT1080 cells were 
grown on 6-well plates (Sarstedt). 3x105 cells were seeded per well in the 6-well plates and 
transfected 24 hours later with 0.05µg of plasmids containing E1A constructs fused to 
GAL4 DNA binding domain (DBD) (plasmids 49-52, Table 2.1), or an empty GAL4 DBD 
vector (plasmid 47, Table 2.1); increasing concentrations of HA-tagged BS69 constructs 
(plasmids 39-41, Table 2.1); 0.5µg of luciferase reporter vector (plasmid 48, Table 2.1); 
and an empty pcDNA3 HA vector as required (plasmid 38, Table 2.1) to ensure a total 
amount of 2µg DNA transfected per well. Transfections were carried out using X-
tremeGene HP DNA Transfection Reagent (Roche) according to the manufacturer’s 
protocol.  
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2.6 Co-Immunoprecipitation 
HT1080 cells were harvested 24 hours post-transfection using a cell scraper. The cells were 
pelleted in a centrifuge at 500 RCF for 2 minutes at 4oC. The cells were washed with 5mL 
phosphate buffered saline (PBS) (173mM NaCl, 2.7mM KCl, 4.2mM Na2HPO4, and 
1.5mM KH2PO4; all from BioShop), pelleted in a centrifuge at 500RCF, then resuspended 
in 1ml NP-40 lysis buffer (0.5% NP-40, 150mM NaCl, and 50mM Tris-HCl; all from 
BioShop, pH 7) supplemented with 0.5% Protease Inhibitor Cocktail (Sigma). The cells 
underwent lysis on ice for 10 minutes before being processed for 10 minutes in a centrifuge 
at 4oC to pellet cell debris. After centrifugation, the lysates were transferred to new 
centrifuge tubes with 20µl of lysate aliquoted to another tube to be used as a 2% input 
control. 1µl of anti-GFP antibody (Table 2.4) and 120µl of a 10% Sepharose-Protein A 
slurry (Sigma) were added to the remaining 980µl of cell lysate. The samples were then 
incubated for 2 hours at 4oC with gentle rocking. After the incubation period, the samples 
were pelleted at 500RCF in a centrifuge for 30 seconds at room temperature and washed 
with NP-40 lysis buffer. The washing process was repeated ten times to reduce nonspecific 
background binding. The Sepharose-antibody-protein complexes were resuspended in 25µl 
of 2X loading dye (49% NuPAGE LDS Sample Buffer from Thermo Fisher supplemented 
with 0.21M DTT from BioShop), while 10µl of 3X loading dye (70% NuPAGE LDS 
Sample Buffer from Thermo Fisher supplemented with 0.3M DTT from BioShop) was 
added to the 2% input controls. The input controls and Sepharose-antibody-protein 
complexes were then centrifuged for 30 seconds at room temperature before being 
incubated for 5 minutes at 98oC to denature and separate proteins from the Sepharose 
beads. Samples were then loaded into polyacrylamide gels for western blot analysis. 
 
2.7 Western Blot Analysis 
Samples were loaded into NuPAGE 4-12% Bis-Tris polyacrylamide gradient gels 
(Invitrogen), resolved by electrophoresis at 200V, then transferred to a polyvinylidene 
fluoride (PVDF) membrane (Amersham Hybond from GE Healthcare Life Sciences) using  
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Table 2.4. List of Antibodies Used in this Study 
Target Animal of Origin Usage 
Dilution 
Factor 
from 
Stock 
Company Catalogue Number 
LexA Rabbit polyclonal 
WB 
Primary 1:10000 Millipore 06-719 
HA Rat monoclonal 
WB 
Primary 1:2000 Roche 
1186742300
1 
G6PD Rabbit polyclonal 
WB 
Primary 1:100000 Sigma A-9521 
GST Rabbit polyclonal 
WB 
Primary 1:5000 Sigma G7781 
6xHis Rabbit polyclonal 
PA 
Primary 1:5000 Abcam ab1187 
GFP Rabbit polyclonal Co-IP 1:1000 Clontech 632592 
GFP Rabbit polyclonal 
WB 
Primary 1:2000 Clontech 632592 
BS69 Rabbit monoclonal 
WB/PA 
Primary 1:4000 Abcam EP18343 
Actin Rabbit polyclonal 
WB 
Primary 1:2000 Sigma A-2066 
Tubulin Mouse monoclonal 
WB 
Primary 1:5000 Sigma T6199 
Rat IgG Goat polyclonal 
WB 
Secondary 1:200000 Pierce 31470 
Rabbit IgG Goat polyclonal 
WB/PA 
Secondary 1:10000 
Jackson 
Laboratories 111-035-003 
Mouse IgG Goat polyclonal 
WB 
Secondary 1:10000 
Jackson 
Laboratories 115-035-003 
 
Note: Antibodies in bold are conjugated to HRP 
WB = western blot, PA = peptide array, Co-IP = co-immunoprecipitation  
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the XCell SureLock system (Invitrogen) according to the manufacturer’s protocol. We used 
MES (2-[N-morpholino]ethanesulfonic acid) SDS running buffer (50mM MES, 50mM 
Tris, 3.47mM SDS, and 1.03mM EDTA; all from BioShop) during the gel electrophoresis 
step, and an in-house transfer buffer (25mM Bicine, 25mM Bis-Tris, 1.03mM EDTA, 
20nM Chlorobutanol, and 10% Methanol; Bicine is from BioBasic, all other components 
are from BioShop) during the transfer step. The membranes were briefly soaked in tris 
buffered saline with Tween-20 (TBS-T) (20mM Tris, 136mM NaCl, and 0.1% Tween-20; 
Tween-20 is from Sigma, all other components are from BioShop) before being blocked at 
room temperature with shaking for one hour in 20ml of blocking buffer (5% w/v Skim 
Milk Powder from BioShop in TBS-T) before being incubated at 4oC with shaking 
overnight in 20ml of primary antibody (Table 2.4) diluted in blocking buffer. The 
membranes were washed three times for 10 minutes each in 20ml of TBS-T. The 
membranes were then incubated at room temperature for 30 minutes with shaking in 20ml 
of species specific, horseradish peroxidase (HRP)-conjugated secondary antibody (Table 
2.4) diluted in blocking buffer. The membranes were washed three more times for 10 
minutes each in 20ml of TBS-T before using Luminata Crescendo Western HRP Substrate 
(Millipore) to detect protein according to the manufacturer’s protocol. Images were 
developed on Amersham Hyperfilm enhanced chemiluminescence (ECL) membrane (GE 
Healthcare Life Sciences) using an automated film processor (Konica Minolta SRX-101A) 
according to the manufacturer’s protocol.  
 
2.8 Bradford Assay 
Protein standards were created using 1, 2, 5, 10, 20, and 40µg/ml bovine serum albumin 
(BSA) (Sigma) in 800µl of ddH2O. Samples to be measured were diluted 1:100 in ddH2O 
to a final volume of 800µl. Next, 200µl of Protein Assay Dye Reagent (Bio-Rad) was added 
to the protein standards and samples (Bradford, 1976). After thorough mixing, 200µl of the 
solutions were loaded per well in duplicate into 96 well plates (Thermo Fisher). The 96 
well plates were then read using the Multiskan Ascent plate reader (Thermo Fisher) 
according to the manufacturer’s protocol. Data analysis was performed using Ascent 
Software (version 2.6, Thermo Fisher). 
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2.9 Luciferase Assay 
HT1080 cells were harvested 24 hours post-transfection using a cell scraper. The cells were 
pelleted in a centrifuge at 500RCF for 2 minutes at room temperature and washed with 1ml 
of PBS. The cells were then resuspended in 200µl of Luciferase Cell Culture Lysis Reagent 
(Promega). The cells underwent lysis on ice for 10 minutes before being processed in a 
centrifuge for 10 minutes at 4oC to pellet cell debris. After centrifugation, the lysates were 
transferred to new centrifuge tubes. Next, 20µl of lysates were aliquoted to verify protein 
expression using western blot analysis (Section 2.7), 8µl of lysates were aliquoted to 
measure total protein concentration using a Bradford Assay (Section 2.8), and 50µl of 
lysates were transferred to polystyrene test tubes (Fisher) to detect luciferase production. 
To detect luciferase production, 50µl of Luciferase Assay Substrate (Promega) was added 
to each sample immediately prior to light detection by the Lumat LB 9507 luminometer 
(Berthold). Measuring time was set to 10 seconds. Luciferase activity was first normalized 
to total protein concentration, then calculated as fold increase over that of cells transfected 
with an empty pM vector in place of a pM vector containing an E1A construct (Table 2.1).  
 
2.10 siRNA Knockdown 
Cells were seeded at a concentration of 3x105 cells per well in 6 well plates. IMR-90 cells 
were transfected 24 hours after being seeded, while A549 cells were transfected 4 or 24 
hours after being seeded. Downregulation of BS69 was performed using siRNA from 
Thermo Fisher (Silencer Select siRNA ID: s21153 and s21154) or Dharmacon (ON-
TARGETplus SMARTpool). Downregulation of protein kinase A (PKA) Type 1a 
regulatory subunit was performed using siRNA from Thermo Fisher (Silencer Select 
siRNA ID: s286). The final concentration of siRNA transfected was 10nM or 20nM. 
Transfections were performed using siLentFect Lipid Reagent (BioRad) according to the 
manufacturer’s protocol, using either 2µl or 4µl of the lipid transfection reagent per well 
for the 10nM and 20nM transfections respectively. Scrambled siRNA (Silencer Negative 
Control No.2, Ambion) was used as a negative control. Bradford Assays (Section 2.8) were 
used to ensure equal loading for western blot analysis.  
59 
 
2.11 Quantitative Reverse Transcription PCR 
A549 cells were harvested 48 hours post-transfection using a cell scraper. Total RNA was 
extracted using the PureLink RNA Mini Kit (Thermo Fisher) and the PureLink DNase Set 
(Thermo Fisher) according to the manufacturer’s protocol. cDNA was obtained by reverse 
transcribing 1µg of purified RNA using the SuperScript VILO cDNA Synthesis Kit 
(Thermo Fisher) according to the manufacturer’s protocol. cDNA quantification via 
quantitative PCR (qPCR) was completed using the Power SYBR Green PCR Master Mix 
kit (Thermo Fisher) according to the manufacturer’s protocol with 75ng cDNA per sample 
and 10µM oligonucleotide primers (BS69 F: GCAACACAGCACAAGCAACT, BS69R: 
GTACATGGCCTCCTCCTCAC). Measurements were taken on the QuantStudio 5 Real-
Time PCR System (Thermo Fisher). Results were analyzed using the 2-ΔΔCT method, using 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the internal control and 
normalizing data to that of cells transfected to scrambled siRNA (Livak & Schmittgen, 
2001; Vandesompele et al., 2002). No template and no reverse transcription controls were 
used to assess the presence of primer dimers and DNA contamination.  
 
2.12 Purification of 6xHis and GST Tagged Proteins 
Protein purification was completed using BL21 (DE3) RIL Escherichia coli. Cells 
transformed with pGEX4T1 or pET28a vectors (Table 2.1) were grown overnight in 5ml 
of LB supplemented with either chloramphenicol (Cam) (68µg/ml) and Amp (50µg/ml), or 
Cam (68µg/ml) and kanamycin (Kan) (20µg/ml) respectively. The overnight cultures were 
then diluted into 500ml of LB supplemented with antibiotics and grown with shaking at 
37oC until OD600 reached 0.5. To induce exogenous protein production, Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1mM before incubating 
the cultures overnight with shaking at 16oC. The cells were then pelleted in a centrifuge at 
5500RCF at 4oC for 10 minutes before being frozen at -80oC overnight. The cells were 
then lysed using 20ml of an in-house lysis buffer (1mM phenylmethylsulfonyl fluoride 
(PMSF), 1mg/ml lysozyme, 2% Triton X-100, 100µM ZnCl; all from Bioshop) to purify 
glutathione S-transferase (GST)-tagged proteins, or lysis buffer supplemented with 20mM 
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imidazole (Bioshop) to purify 6xHis-tagged proteins. The lysates were then incubated with 
shaking at 37oC for 1 hour before being sonicated three times for 15 seconds each at 50% 
of the microtip limit using a Vibracell sonicator (Sonics and Materials). The lysates were 
then centrifuged at 5500RCF at 4oC for 10 minutes to pellet cell debris. 3ml of Nickel-
NTA (Qiagen) or 3ml of Glutathione 4 Fast Flow (GE Healthcare Life Sciences) slurries 
were loaded into 20ml chromatography columns (Bio-Rad). The columns were then 
equilibrated using two 20ml washes of PBS. The cell lysates were then run through the 
corresponding chromatography columns. The glutathione columns were washed three 
times with 20ml of PBS per wash, while the nickel columns were washed three times with 
20ml of PBS supplemented with 20mM imidazole per wash. Ten 1ml fractions were 
collected by eluting the columns with either 10mM glutathione (BioShop) in PBS, or 
250mM imidazole in PBS. Samples were collected before IPTG was added, after overnight 
growth in IPTG, after lysate flow-through, and after wash steps to monitor protein 
expression and column affinity. 
 
2.13 Coomassie Blue Staining 
Coomassie blue staining of polyacrylamide gels were completed as previously described 
(Neuhoff et al., 1988). After electrophoresis, polyacrylamide gels were incubated with 
shaking at room temperature in Coomassie staining solution (50% methanol, 0.05% 
Coomassie Brilliant Blue R-250, 10% acetic acid; all from BioShop) for one hour. The gels 
were then rinsed with water before being incubated with shaking at room temperature in 
detain solution (30% methanol, 10% acetic acid; all from BioShop) and paper towels to 
draw up excess Coomassie Blue dye. Paper towels and destain solution were changed as 
needed until the gel background was clear of excess blue colouration.  
 
2.14 Peptide Array 
Peptide arrays were provided by the laboratory of Dr. Shawn Li (University of Western 
Ontario) and were synthesized using previously described methods (Frank, 2002; Huang 
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et al., 2008). Design for the positional scanning library was completed using the Genscript 
online peptide array design tool. Arrays were synthesized using Fmoc solid-phase peptide 
synthesis on amino-functionalized cellular membranes (Whatman) automated by the 
MultiPep RSI Peptide Synthesizer (Intavis) according to the manufacturer’s protocol. After 
the array was synthesized, the peptides on the membranes were deprotected for 1.5 hours 
using a trifluoroacetic acid (TFA) cocktail solution (95% TFA, 3% triisopropylsilane  
(TIPS) in ddH2O). The membranes were washed with dichloromethane (DCM) three times 
for 2 minutes each, then with dimethylformamide (DMF) three times for 2 minutes each, 
and finally with absolute ethanol three times for 2 minutes each. The membranes were then 
left overnight to air dry and stored in -20oC. The membranes were reactivated by immersion 
in 50% ethanol for 15 minutes, followed by a 15-minute incubation in ddH2O. The 
membranes were then blocked in 3% BSA at 4oC overnight with shaking before being 
probed with 1µM 6xHis-tagged BS69 in 3% BSA at 4oC overnight with shaking. The 
membrane was then washed with PBS three times for 10 minutes each and then incubated 
in HRP-conjugated anti-6xHis tag antibody (Table 2.4) diluted in 3% BSA for one hour. 
The membranes were washed three more times for 10 minutes in PBS before using 
Luminata Crescendo Western HRP Substrate (Millipore) to detect protein according to the 
manufacturer’s protocol. The membrane was imaged using a Gel Doc XR (Bio-Rad). 
To strip the membrane, the array was washed with shaking with 20ml H2O three times for 
10 minutes each. The membrane was then incubated with 20ml of stripping mix A (8M 
urea, 1% SDS in PBS) in a sonication bath at 40oC three times for 10 minutes each. The 
membrane was then incubated with shaking using 20ml of stripping mix B (10% acetic 
acid, 50% ethanol in H2O) three times for 10 minutes each, followed by incubation with 
shaking using 20ml of absolute ethanol three times for 10 minutes each. Finally, the 
membranes were washed with shaking using PBS three times for 5 minutes each. After this 
process, the membrane was blocked in 3% BSA at 4oC overnight with shaking before being 
probed as necessary. 
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2.15 Homology Modelling 
Protein sequences from all 21 ZMYND gene family members were obtained from Uniprot 
and aligned using Clustal Omega (Goujon et al., 2010; Sievers et al., 2011). The 
phylogenetic tree was then visualized using FigTree (version 1.4.2). The closest relative of 
BS69 with a pre-existing structural data, which is ZMYND5, was used as the template for 
the homology model. The ZYMND5 structural data file (PDB ID: 4A24) was obtained 
from RCSB online repository and visualized using UCSF Chimera (version 1.9) (Kateb et 
al., 2013). The MODELLER plugin was used to construct the homology model (Webb & 
Sali, 2016). 
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3 Results 
 
3.1 Mapping the Interaction Between E1A and BS69 
3.1.1 Using Homology Modelling to Construct the MYND Domain 
of BS69 
The cellular environment consists of complex and dynamic networks of protein-protein 
interactions. Each constituent in these networks plays a specific role in ensuring the 
functionality of a larger encompassing biochemical pathway. To fully understand the 
details of a specific protein-protein interaction, a model with atomic-level resolution is 
typically required. These models can be determined experimentally using several 
techniques including protein crystallography and nuclear magnetic resonance (NMR) 
spectroscopy. Unfortunately, both these techniques require highly purified protein and each 
have their own unique challenges and limitations as well: obtaining high quality crystals is 
difficult for crystallography, while NMR is limited to smaller proteins (Yee et al., 2005). 
An alternative to experimentally determining protein structures is to use in silico methods 
such as homology modelling and protein-ligand docking. A homology model of the BS69 
MYND domain based on DEAF-1, or ZMYND5, was previously constructed by the Sattler 
group in 2013 (Kateb et al., 2013). Thus, we set out to re-create this homology model, and 
use it to analyze the interaction between E1A and the MYND domain of BS69 by using 
protein-ligand docking. 
To construct a homology model of the MYND domain, we first performed a multiple 
sequence alignment of all the known ZMYND (ZMYND1-21, 23) family of proteins 
(Figure 3.1A). Protein sequences were obtained from UniProt and the multiple sequence 
alignment was completed using Clustal Omega (Goujon et al., 2010; Sievers et al., 2011). 
A phylogenetic tree was also created using Clustal Omega, which was then used to 
determine the closest relative of BS69 with a preexisting structure (Figure 3.1B). 
ZMYND5 was chosen as the template to create the homology model using the 
MODELLER plugin in UCSF Chimera (Webb & Sali, 2016). ZMYND5 is shown in the  
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Figure 3.1. Homology model of the BS69 MYND domain. A) Multiple sequence 
alignment of the MYND domains of 21 proteins of the ZMYND family. BS69 
(ZMYND11) is highlighted in yellow. The cysteine and histidine residues used to 
coordinate zinc ions are labelled in the same scheme as Figure 6. Residues with high 
conservation are shown in blue, with darker shading indicating higher levels of 
conservation. Sequence alignment was generated using Clustal Omega. B) Phylogenetic 
tree of the 21 members of the ZMYND family of proteins. BS69 is highlighted in blue. 
ZMYND5, immediately below BS69, was used as the template for the homology model. 
C) Ribbon structures of ZMYND5 (PDB: 4A24) and the BS69 homology model (Kateb 
et al., 2013). ZMYND5 is shown in silver in the first row, while the homology model is 
shown in yellow in the third row. An overlay of the two structures is shown in the second 
row. The structures on the left depict the side of the protein that interacts with E1A and 
NCOR2, while the structures on the right depict a 90° rotation along the Y axis. Zinc ions 
are shown as grey spheres. Side chains of the cysteine and histidine residues used to 
coordinate the zinc ions are shown. The sulfur and nitrogen atoms are coloured yellow 
and blue respectively. Ribbon structures of ZMYND5 adapted from (Kateb et al., 2013). 
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top row in silver, the BS69 homology model is on the bottom row in yellow, and the middle 
row shows a superimposed image of both models (Figure 3.1C). The models are depicted 
using ribbon diagrams, with the zinc ions shown as grey spheres and the zinc-coordinating 
histidine and cysteine side chains protruding from the ribbon.  
Protein-ligand docking was then completed using ClusPro (Kozakov et al., 2017). The PDB 
file of the BS69 MYND homology model was uploaded as the receptor, and a flexible 
peptide with the E1A derived sequence “SMPNLVPEVI” was created in UCSF Chimera 
and submitted as the ligand. The top row shows the interaction between a peptide from 
nuclear receptor co-repressor 2 (N-CoR2) and the DEAF-1 MYND domain (Figure 3.2A), 
the middle row shows the structure of an EBNA2 peptide interacting with the BS69 MYND 
domain (Figure 3.2B), and the bottom row shows the structure generated by protein-ligand 
docking of the BS69 MYND homology model with the submitted E1A peptide (Figure 
3.2C) (Harter et al., 2016; Liu et al., 2007). The N-CoR2 peptide contains a PXLXS 
(sequence: TISNPPPLISSAK) motif located in the same spatial position as the PXLXP 
motif for EBNA2 (sequence: SMPELSPVL) and E1A (sequence: SMPNLVPEVI). The 
ligands are shown in green and the core motif is shown in red. The central leucine residue 
in the PXLXS and PXLXP core motifs of N-CoR2 and EBNA2 are directed inwards 
towards the MYND domain of DEAF-1 and BS69 MYND, but the leucine residue in E1A 
is directed away from BS69 MYND. However, the proline residues of the EBNA2 and 
E1A peptides share similar orientations. Thus, this homology model may be somewhat 
useful in helping visualize the E1A-BS69 protein-protein interaction and predicting 
residues that make contact between these two proteins. However, precise conclusions about 
the interaction mechanism should not be drawn by solely referring to this model and must 
be validated using other experimental approaches.  
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Figure 3.2. Protein-ligand docking of E1A and the MYND domain of BS69. NMR 
ribbon structures of A) NCOR2 peptide in complex with DEAF-1 MYND (PDB: 2ODD) 
and B) EBNA2 peptide in complex with BS69 MYND (PDB: 5HDA) are shown in the 
first two rows (Harter et al., 2016; Liu et al., 2007). C) Protein-ligand docking of an E1A 
peptide in complex with the homology model of BS69 MYND. The NCOR2 peptide 
consists of residues 1109-1121 with the sequence TISNPPPLISSAK, the EBNA2 peptide 
consists of residues 381-389 with the sequence SMPELSPVL, and the E1A peptide 
consists of residues 111-120 with the sequence SMPNLVPEVI. Peptides are shown in 
green, with the PXLXS or PXLXP motif shown in red. The MYND domains of the 
various proteins are show in beige. NCOR2 in complex with DEAF-1 MYND adapted 
from (Liu et al., 2007). EBNA2 peptide in complex with BS69 MYND adapted from 
(Harter et al., 2016). 
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3.1.2 Determining Conservation of the Interaction between BS69 
and E1A of Adenovirus Species A-F 
The interaction between E1A and BS69 was initially discovered through an E1A pulldown 
screen performed by the Bernards group in 1995 (Hateboer et al., 1995). Subsequent 
studies on this interaction have all been conducted using E1A from HAdV-5 (Ansieau & 
Leutz, 2002). Yet, interactions between E1A and other important host factors, such as pRb, 
p300, and PKA, are conserved amongst many other adenovirus species (Avvakumov et al., 
2004; King et al., 2016; Pelka et al., 2008). Important functions of a protein are more likely 
to be conserved between different species, so we set out to determine if E1A from other 
adenovirus species can interact with BS69.  
We completed these experiments using yeast two-hybrid assays. We used E1A from 
HAdV-3, 4, 5, 9, 12, and 40, which are representative types from adenovirus species B, E, 
C, D, A, and F respectively (Figure 3.3). Yeast expression vectors containing E1A CR2 
from each adenovirus type in a bait vector, the MYND domain of BS69 in a prey vector, 
and a yeast two-hybrid reporter vector were transformed into W303-1A yeast. We chose 
to use constructs expressing only CR2 instead of full length E1A to reduce background 
activity, as the N-terminus and CR3 both facilitate intrinsic transcriptional activation by 
E1A (Ablack et al., 2010). The negative control consisted of yeast transformed with 
HAdV-5 E1A CR2, an empty prey plasmid, and the reporter vector. The yeast were 
incubated for 72 hours in selective agar plates before being picked for overnight growth in 
selective liquid media. The liquid cultures were then processed, and β-galactosidase 
activity in Miller units was calculated. Significance markers are assigned in comparison to 
the negative control (Figure 3.3). 
The interaction between BS69 and E1A is conserved in HAdV-5, 9, and 12, but not HAdV-
3, 4, and 40 (Figure 3.3A). The activity in Miller units for the interaction between BS69 
and E1A from HAdV-5, 9, and 12 are significantly higher than the negative control by 28-
, 118-, and 119-fold respectively. Interestingly, the PXLXP motif is present in E1A from 
all HAdV species that are able to interact with BS69, while absent in E1A from species  
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Figure 3.3. Conservation of the interaction between BS69 and E1A in different 
adenovirus species. A) Yeast two-hybrid assay of E1A CR2 of HAdV-3, 4, 5, 9, 12, and 
40 in bait and BS69 MYND in prey in W303-1A yeast. β-galactosidase activity in Miller 
units is shown on the Y-axis, while the adenovirus species are indicated on the X-axis. 
The negative control (Neg) consists of yeast transformed with E1A CR2 of HAdV-5 in 
bait and an empty prey vector. Results are shown as mean ± SD, n=3. Significance 
markers are assigned in comparison to the negative control (ns = not significant; * p ≤ 
0.05; one-way ANOVA with Dunnett’s multiple comparisons test). B) Multiple sequence 
alignment of E1A CR2 of HAdV-3, 4, 5, 9, 12, and 40. Alignment was completed using 
Clustal Omega. The PXLXP motifs are outlined in red boxes. Residues with high 
conservation are shown in blue, with darker shading indicating higher levels of 
conservation.   
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that are unable to interact with BS69 (Figure 3.3B). Because most molecular reagents used 
to study adenoviruses have been constructed using the HAdV-5 genome, the majority of 
this project will focus on E1A from HAdV-5. 
 
3.1.3 Defining the Minimal Interaction Region on HAdV-5 E1A for 
BS69 
The PXLXP motif was defined by the Leutz group in 2002 by sequence comparison of 
E1A and ENBA2, which is a protein from Epstein Barr Virus (EBV) that is also able to 
interact with BS69 (Ansieau & Leutz, 2002). This motif is present not only in viral proteins, 
but also on host proteins such as skeletal α-nascent polypeptide-associated complex 
(skNAC) and chromatin assembly factor 1 (CAF1), which use the PXLXP motif to mediate 
interactions with the MYND containing proteins m-Bop and C-C motif chemokine receptor 
4 (CCR4) respectively (Chou et al., 2017; Sims et al., 2002). The core PXLXP motif on 
E1A is necessary but not sufficient to mediate a strong interaction with BS69. This 
phenomenon is also true for other E1A interactors, including the LXCXE-mediated 
interaction with pRb (DeCaprio, 2009). Determining the minimal interacting region allows 
us to better understand the mechanism of interaction, and would help improve the 
experimental design of our proposed peptide array experiment. This information will allow 
us to use the shortest possible peptide sequences for the array, leading to decreased cost 
and increased sequence fidelity of the synthesized peptides. Thus, we set out to determine 
the minimal number of flanking residues outside of the core PXLXP motif required for 
E1A to interact strongly with BS69.  
This set of experiments was completed using yeast two-hybrid assays. We used a series of 
HAdV-5 E1A truncation mutants denoted T1 (SMPNLVPEVI, residues 111-120) through 
T8 (PNLVP, residues 113-117) in bait, the MYND domain of BS69 in prey, and a LacZ 
reporter vector transformed into W303-1A yeast (Figure 3.4). The negative control 
consisted of yeast transformed with E1A CR2, an empty prey plasmid, and the reporter 
vector. Transformed yeast were grown for 72 hours on selective agar plates before being 
picked for overnight growth in selective liquid media. The liquid cultures were then  
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Figure 3.4. Determining the minimal interacting region on E1A required to bind 
with BS69. A) Yeast two-hybrid assay of E1A truncation mutants in bait and BS69 
MYND in prey in W303-1A yeast. Sequences of the E1A truncation mutants with the 
corresponding designations are shown above the graph. β-galactosidase activity in Miller 
units is shown on the Y-axis, while the truncation mutants are indicated on the X-axis. 
The negative control (Neg) consisted of yeast transformed with E1A CR2 in bait and an 
empty prey vector, while the positive control (CR2) consisted of yeast transformed with 
E1A CR2 in bait and BS69 MYND in prey. Results are shown as mean ± SD, n=4. 
Significance markers are assigned in comparison to the negative control (ns = not 
significant; * p ≤ 0.05; one-way ANOVA with Dunnett’s multiple comparisons test). B) 
Western blot of yeast cell lysate to verify protein expression. Negative control is labelled 
as CR2 / Vector. Bait and prey proteins were visualized using anti-LexA DBD and anti-
HA antibodies respectively. G6PD was used as a loading control.  
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processed, and β-galactosidase activities in Miller units were calculated. Significance 
markers were assigned in comparison to the negative control (Figure 3.4A). Compared to 
the entire E1A CR2 fragment, the truncation mutant T4, indicated in green with the 
sequence MPNLVPEV, was the shortest mutant that interacted with BS69 at levels 
comparable to CR2 (Figure 3.4A). Subsequent removal of the C-terminal valine (T5) and 
the N-terminal methionine (T6) resulted in stepwise decreases in binding activity. T4 and 
T5, in red, showed a 35- and 12-fold increase in activity over the negative control 
respectively, while the T6 and further truncations were totally defective for binding in this 
assay. Notably, the CR2 positive control exhibited less activity than truncation mutants T1-
T4 possibly due to steric hindrance or competitive binding with other E1A interactors in 
this region, such as UBC9. Western blots of yeast lysate ensured these observations were 
not simply due to reduced protein expression by the non-binding truncation mutant fusion 
proteins (Figure 3.4B). The division between the blots show the samples being run and 
probed concurrently on separate gels. Glucose-6-phosphate dehydrogenase (G6PD) was 
used as the loading control for both gels. I also performed a second set of experiments 
using constructs that included a flexible linker, with the sequence SGG, between the LexA 
DNA binding domain and the E1A truncation peptide (Figure 3.5A). The inclusion of this 
linker in the fusion protein resulted in increased β-galactosidase activity of approximately 
100 Miller units for truncation mutants T1 and T5, but did not increase the β-galactosidase 
activity for a negative control where the yeast were transformed with an empty prey vector 
(Figure 3.5B).  
E1A CR2 contains many overlapping interaction motifs used to bind to pRb, BS69, UBC9, 
the S2 component of the 19S regulatory complex of the proteasome, and more recently, 
STING (Lau et al., 2015; Pelka et al., 2008). Because of this, designing a specific mutant 
that abrogates binding with BS69 without affecting the neighbouring interacting partners 
is challenging.  After finding the minimal interacting region, we set out to determine which 
residues within this region are important in binding to BS69. To accomplish this, we used 
another series of yeast two-hybrid assays.  
Alanine scanning mutants denoted M1 (E1A S111A) through M10 (E1A I120A) in the 
context of CR2 in bait, the MYND domain of BS69 in prey, and a reporter vector were  
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Figure 3.5. The effects of including a flexible SGG linker on the measurement of 
E1A-BS69 interactions using the yeast two-hybrid assay. A) Diagrammatic 
representation of E1A truncation mutants in bait with or without flexible linkers. 
Sequences of the T5 and T1 truncation mutants with or without SGG linkers are shown. 
B) Yeast two-hybrid assay of E1A truncation mutants, with or without SGG linkers, in 
bait and BS69 MYND in prey in W303-1A yeast. β-galactosidase activity in Miller units 
is shown on the Y-axis, while the truncation mutants are indicated on the X-axis. Negative 
controls (T5 – No Linker Neg and T5 – Linker Neg) consisted of yeast transformed with 
the respective bait proteins with an empty prey vector. Results are shown as values from 
a single experiment.  
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transformed into W303-1A yeast (Figure 3.6A). The negative control consisted of yeast 
transformed with E1A CR2, an empty prey plasmid, and the reporter vector. The wildtype 
positive control was similar to the negative control, except with the MYND domain of 
BS69 in prey. The transformed yeast were grown for 72 hours on selective agar plates 
before being picked for overnight growth in selective liquid media. The liquid cultures 
were processed, and β-galactosidase activity in Miller units was calculated. Significance 
markers were assigned in comparison to the wildtype positive control (Figure 3.6B). 
E1A constructs M3 and M5, which correspond to the P113A and L115A point mutations 
respectively, showed significantly decreased binding affinity to BS69, at 4- and 18-fold 
less respectively, compared to the wildtype control (Figure 3.6B). Both these mutants target 
the PXLXP core motif. Interestingly, the M7 construct, which corresponds to the P117A 
point mutant, did not show significantly different binding affinity to BS69 compared to the 
wildtype control, even though this mutant targets the C-terminal proline residue in the 
PXLXP motif. Yeast transformed with wildtype E1A CR2 in bait, with an empty prey 
vector was used as a negative control. 
Concurrently with the alanine scanning mutation panel, we also constructed several double 
and triple point mutants to create an E1A construct that thoroughly abrogates binding with 
BS69. To help with the design of these point mutants, we referred to an NMR structure of 
an EBNA2 peptide in complex with the MYND domain of BS69 (Harter et al., 2016). We 
targeted M112, P113, L115, and P117 for mutation, as the side chains of these residues 
protrude towards and make direct contact with the BS69 MYND domain (Harter et al., 
2016). Once again, we used a series of yeast two-hybrid assays by transforming E1A 
double and triple point mutants denoted M11 through M15 in the context of CR2 in bait, 
the MYND domain of BS69 in prey, and a reporter vector into W303-1A yeast (Figure 
3.7A). All double and triple mutants showed significantly decreased binding affinity to 
BS69, at approximately 60-fold less, compared to a wildtype control (Figure 3.7B). We 
wanted to ensure the decrease in activity was not due to decreased protein expression 
levels, so we performed a western blot on yeast cell lysate for each vector (Figure 3.7C). 
All the proteins, except for the M12 bait, were expressed as expected. G6PD was used as 
the loading control.   
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Figure 3.6.  Using alanine scanning mutagenesis to determine the critical residues 
within the E1A minimal interacting region required to bind to BS69. A) Sequences 
of the E1A alanine scanning mutants with the corresponding designations. The PXLXP 
interaction motif is highlighted in red. The alanine substitutions in the sequences are also 
in red and bold. B) Yeast two-hybrid assay of E1A alanine scanning mutants, in the 
context of CR2, in bait and BS69 MYND in prey in W303-1A yeast. β-galactosidase 
activity in Miller units is shown on the Y-axis, while the alanine scanning mutants are 
indicated on the X-axis. The negative control (Neg) consisted of yeast transformed with 
wildtype E1A CR2 in bait and an empty prey vector, while wildtype (WT) the positive 
control consisted of yeast transformed with E1A CR2 in bait and BS69 MYND in prey. 
Results are shown as mean ± SD, n=3. Significance markers are assigned in comparison 
to the WT positive control (* p ≤ 0.05; one-way ANOVA with Dunnett’s multiple 
comparisons test). 
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Figure 3.7. Introducing double and triple point mutations within E1A to thoroughly 
abrogate its ability to interact with BS69. A) Sequences of the E1A double and triple 
point mutants with the corresponding designations. The PXLXP interaction motif is 
highlighted in red. The double and triple point mutants in the sequences are also in red 
and bold. B) Yeast two-hybrid assay of E1A double and triple point mutants, in the 
context of CR2, in bait and BS69 MYND in prey in W303-1A yeast. β-galactosidase 
activity in Miller units is shown on the Y-axis, while the double and triple point mutants 
are indicated on the X-axis. The negative control (Neg) consisted of yeast transformed 
with E1A CR2 in bait and an empty prey vector, while the positive control (WT) consisted 
of yeast transformed with wildtype E1A CR2 in bait and BS69 MYND in prey. Results 
are shown as mean ± SD, n=3. Significance markers are assigned in comparison to the 
WT positive control (* p ≤ 0.05; one-way ANOVA with Dunnett’s multiple comparisons 
test). C) Western blot of yeast cell lysate to verify protein expression. Bait and prey 
proteins were visualized using anti-LexA DBD and anti-HA antibodies respectively. 
G6PD was used as a loading control. 
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3.1.4 Purifying the MYND domain of BS69 
With the goal of using recombinant BS69 to probe an array of peptides based on the E1A 
interaction sequence, we purified the MYND domain of BS69 using affinity 
chromatography. The MYND domain of BS69 was fused to GST or 6xHis epitope tags 
using the pGEX4T1 or pET28a backbone vectors respectively. The vectors were then 
transformed into BL-21 Escherichia coli. Selected colonies were expanded in LB liquid 
culture medium until OD600 reached 0.5, before treatment with IPTG to induce exogenous 
protein expression and further growth overnight at 16oC. The cell lysates were then eluted 
through a glutathione or Nickel-NTA column for GST and 6xHis tagged proteins 
respectively. Samples were collected at various steps to measure the quality of protein 
purification. MYND-His in the pET28a backbone has a molecular weight of 25kDa, which 
corresponds to the prominent band in the elution lanes on the gel stained with Coomassie 
Blue (Figure 3.8A). Some samples were also analyzed using a western blot probed with an 
anti-BS69 antibody, and the bands in the elution lanes show a laddering effect with the 
molecular weights in multiples of 25kDa (Figure 3.8B). This indicates that the protein is 
forming polymers, possibly due to the shortage of zinc ions that are coordinated by cysteine 
and histidine residues within the MYND domain. Thus, we repeated the purification 
protocol of both GST and His tagged MYND, except we supplemented the growth media 
with 100µM ZnCl. MYND-GST has a molecular weight of 47kDa, and is the only 
detectable band in the elution lanes on the gel stained with Coomassie Blue (Figure 3.9). 
The MYND-His purification resulted in a similar blot to the previous attempt, in that the 
25kDa band is still prominent on the Coomassie Blue gel. We have also completed 
preliminary protein purification of pRb-GST (residues 385-773) and UBC9-GST at three 
different post-IPTG incubation temperatures, and detected the protein using a western blot 
probed using an anti-GST antibody (Figure 3.10).  
 
3.1.5 Mapping the E1A-BS69 Binding Site Using a Peptide Array 
Peptide arrays are a powerful tool used for high-throughput epitope mapping, enzyme 
profiling, phosphorylation studies, and protein-protein interactions. These arrays provide  
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Figure 3.8. Coomassie Blue gel and Western blot showing His tagged MYND 
protein purification. 6xHis-tagged BS69 MYND was expressed in BL21 (DE3) RIL 
Escherichia coli and induced using 1mM IPTG. Samples were collected before adding 
IPTG (Pre-IPTG), after 24 hour IPTG induction (Post-IPTG 1), after -80oC overnight 
freezing (Post-IPTG 2), after being passed through the Nickel-NTA column (Flow 
Through), and after 11 elution fractions. A) Coomassie Blue-stained gel of the various 
samples collected throughout the purification process. The ladder is labelled in kDa and 
shown on the leftmost lane. Expected molecular weight of 6xHis-tagged BS69 MYND 
is 27kDa. B) western blot showing elution fractions 1, 4, 7 and Post-IPTG 1. The ladder 
is labelled on the left in kDa and the membrane was probed with an anti-BS69 antibody. 
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Figure 3.9. Coomassie Blue gel showing His and GST tagged MYND protein 
purification. Coomassie Blue stained gel of the various samples collected throughout the 
protein purification process. GST and 6xHis-tagged BS69 MYND were expressed in 
BL21 (DE3) RIL Escherichia coli grown in 100µM ZnCl and induced using 1mM IPTG. 
Samples were collected before adding IPTG (Pre-IPTG), after 24 hour IPTG induction 
(Post-IPTG), and after 10 elution fractions. The ladder is labelled in kDa and shown on 
the leftmost lane. Expected molecular weight of GST and 6xHis-tagged BS69 MYND are 
47kDa and 27kDa, respectively. 
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Figure 3.10. Western blot showing protein purification of GST tagged pRb and 
UBC9. Western blot showing purification of GST-tagged pRb and UBC9. GST-tagged 
pRb and UBC9 were expressed in BL21 (DE3) RIL Escherichia coli and induced using 
1mM IPTG for 4, 8, and 16 hours at 37oC, 24oC, and 16oC, respectively. The ladder is 
labelled on the left in kDa and the membrane and the membrane was probed with an anti-
GST antibody. 
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quick results and are cost-efficient to run. Using information from our minimal interacting 
region experiments, we designed a peptide array to characterize the protein-protein 
interaction between E1A and BS69. Because the amino acids at every position in the 
interaction motif under investigation were mutated to every other residue, this experiment 
allows us to address a major shortcoming of the alanine scanning panel we previously 
completed, in which every residue is replaced only with alanine (Figure 3.6).  
We used positional scanning mutagenesis on 14-residue E1A sequences from HAdV-5 and 
HAdV-12 (wildtype HAdV-5 E1A sequence: VSMPNLVPEVIDLT and wildtype HAdV-
12 E1A sequence: ECMPQLHPEDMDLL) to generate a peptide library. These peptides 
were synthesized directly onto a Whatman filter paper membrane using Fmoc solid-phase 
synthesis. We then blocked the membrane and probed it with purified MYND-His followed 
by probing with HRP-conjugated anti-His antibody (Figure 3.11). The blot showed high 
background with intense signals in the lane where the amino acids were sequentially 
mutated into arginine. Most of the spots corresponding to the wildtype sequence (circled 
in red) did not show strong signal strength. We stripped the membrane and re-probed using 
purified MYND-His followed by anti-BS69 antibody and a secondary HRP-conjugated 
anti-Rabbit IgG antibody (Figure 3.12). The results were similar to the previous attempt, 
as there was high background with intense signals in the arginine lane and weak signal 
strength for the wildtype sequences. Finally, we stripped the membranes and re-probed 
with the HRP-conjugated anti-His antibody without prior incubation of the purified 
MYND-His protein (Figure 3.13). We found that the high background signal remained on 
many of the spots. This protocol should be optimized with more stringent blocking steps, 
higher purity protein, and a more specific antibody for future experiments. 
 
3.1.6 Verifying the E1A-BS69 Interaction in a Mammalian Cell 
Culture System 
The previous experiments investigating the E1A-BS69 interaction in this project were 
completed either using purified proteins or in yeast. These model systems have some 
definite advantages, such as being able to measure direct protein-protein interactions or  
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Figure 3.11. Using an anti-6xHis antibody to probe a peptide array showing the 
interaction between the BS69 MYND domain and short peptide sequences from 
HAdV-5 and HAdV-12 E1A. Peptide arrays were provided by the Shawn Li lab and 
synthesized using Fmoc solid-phase peptide synthesis on an amino-functionalized 
cellular membrane. Peptides underwent positional scanning mutagenesis, with the 
corresponding wildtype sequence below the membrane. Each row denotes a position on 
the peptide that is being targeted, with the position labelled left of the membrane. Each 
column represents the amino acid, labelled on the top, that the target residue is mutated 
to. Membranes were blocked overnight with shaking in 3% BSA, then incubated with 
1µM of purified 6xHis-tagged BS69 MYND overnight. The membranes were probed 
using an HRP-conjugated anti-6xHis tag antibody. Peptide spots circled in red denote the 
wildtype sequence. 
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Figure 3.12. Using an anti-BS69 antibody to probe a peptide array showing the 
interaction between the BS69 MYND domain and short peptide sequences from 
HAdV-5 and HAdV-12 E1A. Peptide arrays were provided by the Shawn Li lab and 
synthesized using Fmoc solid-phase peptide synthesis on an amino-functionalized 
cellular membrane. Peptides underwent positional scanning mutagenesis, with the 
corresponding wildtype sequence below the membrane. Each row denotes a position on 
the peptide that is being targeted, with the position labelled left of the membrane. Each 
column represents the amino acid, labelled on the top, that the target residue is mutated 
to. Membranes were blocked overnight with shaking in 3% BSA, then incubated with 
1µM of purified 6xHis-tagged BS69 MYND overnight. The membranes were probed 
using an anti-BS69 antibody followed by an HRP-tagged anti-rabbit IgG secondary. 
Peptide spots circled in red denote the wildtype sequence.  
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Figure 3.13. Using an anti-His antibody to probe the stripped HAdV-5 E1A peptide 
array. Peptide arrays were provided by the Shawn Li lab and synthesized using Fmoc 
solid-phase peptide synthesis on an amino-functionalized cellular membrane. Peptides 
underwent positional scanning mutagenesis, with the corresponding wildtype sequence 
below the membrane. Each row denotes a position on the peptide that is being targeted, 
with the position labelled left of the membrane. Each column represents the amino acid, 
labelled on the top, that the target residue is mutated to. The membranes were stripped 
using a sonication bath in a solution containing urea followed by an acetic acid stripping 
solution. The peptide array was then blocked overnight shaking in 3% BSA. Without 
incubating with purified protein, the membrane was probed using an HRP-conjugated 
anti-6xHis tag antibody. Peptide spots circled in red denote the wildtype sequence. 
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allowing us to quickly screen multiple constructs. However, using these artificial systems 
may compromise biological relevance as the background by which this interaction is 
studied is different from that of a mammalian cellular environment. Thus, we set out to 
verify the E1A-BS69 interaction in a mammalian system by utilizing co-IP experiments in 
HT1080 human fibrosarcoma cells. 
We co-transfected HT1080 cells with equal amounts of HA-tagged BS69 and GFP-tagged 
E1A constructs. These constructs included CR2 (residues 93-139), CR2 CR3 (residues 93-
191), and full length E1A (13S, residues 1-289). Cells transfected with an empty GFP 
vector with or without HA-tagged BS69 were used as negative controls. Cells were lysed 
24 hours post transfection and subject to co-IP using protein A-sepharose beads and an 
anti-GFP antibody. The samples were then run on a western blot and probed with an anti-
HA antibody to determine which E1A constructs could pull down BS69 (Figure 3.14). All 
tested E1A constructs were able to pull down BS69; 13S E1A had the highest affinity, 
followed sequentially by CR2 E1A and CR2 CR3 E1A (Figure 3.14). The faint band 
showing weak interaction between BS69 and E1A CR2 CR3 may be due to weak 
expression or improper folding within CR3 of this E1A construct. BS69 was not pulled 
down by the GFP negative control. 
 
3.2 Analysis of BS69 Mediated Changes on E1A Induced 
Transactivation 
3.2.1 Effects of Increasing BS69 Concentration on E1A Mediated 
Transactivation 
Previous studies in the Bernards lab have shown that BS69 strongly inhibits E1A mediated 
transactivation (Hateboer et al., 1995). In these experiments, the authors used luciferase 
assays to measure transcriptional changes of a reporter vector in cells transfected with 
GAL4-E1A and increasing concentrations of BS69-HA (Hateboer et al., 1995). Other 
studies have shown that the reverse is also true: E1A is able to antagonize BS69 mediated 
repression of cellular genes in a manner dependent on the fidelity of the E1A PXLXP motif 
(Ansieau & Leutz, 2002). Thus, we set out to combine various aspects of all these studies  
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Figure 3.14. Co-immunoprecipitation of E1A constructs and BS69 in HT1080 cells. 
HT1080 cells were co-transfected with 4µg each of HA-tagged BS69 MYND and GFP-
tagged E1A constructs. Negative controls consisted of cells transfected with 4µg of GFP 
vector with and without being cotransfected with 4µg of HA-tagged BS69 MYND. Cell 
lysates were collected 24 hours post transfection and subject to immunoprecipitation 
using an anti-GFP antibody. Samples were subsequently run on a western blot and probed 
with anti-GFP and anti-HA antibodies.   
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to further explore the effects of BS69 on E1A transactivation. Using luciferase assays, we 
verified that BS69 functions as a dose dependent repressor of E1A transactivation, and 
determined that the PXLXP motif is necessary for this observation (Figure 3.15).  
We co-transfected HT1080 cells with a GAL4-responsive luciferase reporter plasmid, 
which contains six GAL4 binding sites upstream of the luciferase reporter gene; a plasmid 
expressing 13S wildtype E1A, or 13S L115A E1A in the GAL4-DBD backbone; increasing 
concentrations of BS69 expressed in the pcDNA3-HA backbone; a pSV-β-galactosidase 
vector, used to measure β-galactosidase activity as an internal transcription control; and an 
empty pcDNA3-HA plasmid as a “stuffer” as required to ensure that 2µg of total DNA was 
transfected per sample (Figure 3.15). β-galactosidase activity was consistent between all 
samples (not shown). 0µg, 0.05µg, 0.2µg, and 0.45µg of BS69 constructs were transfected 
per well. The negative controls consisted of HT1080 cells transfected with the reporter 
plasmid, an empty GAL4-DBD plasmid, and the empty pcDNA3-HA “stuffer” plasmid 
(not shown). The luciferase activity was then measured from the cell lysate, which was 
obtained 24 hours post-transfection. Results were normalized to total protein concentration 
as determined by Bradford assays, then reported as fold activation over the empty GAL4-
DBD negative control.  
In the series of experiments with wildtype E1A, increasing concentrations of BS69 resulted 
in a stepwise and significant decrease in luciferase activity (Figure 3.15). Compared to the 
luciferase activity of cells not transfected with BS69, cells transfected with 0.05µg, 0.2µg, 
and 0.45µg of BS69 showed a 37.4%, 52.9%, and 67.9% decrease in luciferase activity 
respectively. On the other hand, increasing the concentration of BS69 did not significantly 
change the luciferase activity in samples transfected with the L115A E1A construct, which 
is unable to bind BS69 due to the altered PXLXP motif. When comparing cells transfected 
with equal amounts of BS69, luciferase activity was also higher in cells transfected with 
L115A E1A than wildtype E1A. 
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Figure 3.15. BS69 represses E1A mediated transactivation through the PXLXP 
motif. Luciferase assay showing BS69-mediated repression of E1A transactivation. 
Luciferase activity, shown as fold activation over the negative control is labelled on the 
Y-axis, while the amount of BS69 transfected is shown on the X-axis. Black bars 
represent samples co-transfected with wildtype E1A, while grey bars represent samples 
co-transfected with L115A E1A. HT1080 cells were co-transfected with 1µg of pGL2-
(UAS)6-Luc reporter, 0.5µg of pSV-β-galactosidase, 0.05µg pM 13S Ad5 E1A or pM 13S 
E1A L115A, increasing concentrations of HA BS69, and pcDNA3 HA to ensure equal 
loading across all samples. Samples encoding an empty pM vector in place of E1A was 
used as the negative control (not shown). Cell lysates were collected 24 hours post 
transfection and the luciferase activity was measured. Results were normalized by protein 
concentration and reported as fold activity compared to the negative control. Results are 
shown as mean, n=2. Significance markers are assigned in comparison to the samples not 
transfected with a BS69 vector (ns = not significant; * p ≤ 0.05; one-way ANOVA with 
Dunnett’s multiple comparisons test). 
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3.2.2 Determining the Region of BS69 Responsible for Repression 
of E1A Mediated Transactivation 
BS69 is a 602-amino acid protein consisting of four known domains. The PHD, Bromo, 
and PWWP domains are located sequentially in the N-terminal half of the protein. These 
three domains are all involved in mediating the interaction between BS69 and histone 
H3.3K36me3, with the PWWP domain being the most crucial in this interaction (Wang et 
al., 2014; Wen et al., 2014). The MYND domain is a zinc finger near the C-terminus of the 
protein, and this domain is used to form interactions with other proteins including E1A. 
Thus, we set out to determine the domains of BS69 required to repress E1A mediated 
transactivation.  
We co-transfected HT1080 cells with a GAL4-responsive luciferase reporter plasmid; a 
plasmid expressing 13S wildtype E1A or 13S L115A E1A in a GAL4-DBD backbone; 
increasing concentrations of full length (residues 47-602), MYND only (residues 427-602), 
or NO MYND (residues 47-426) constructs of BS69 in the pcDNA3-HA backbone; and 
the pcDNA3-HA “stuffer” plasmid as necessary to ensure that 2µg of total DNA was 
transfected per sample (Figure 3.16). The pSV-β-galactosidase vector was not used in these 
subsequent experiments in order to allow for increased concentrations of transfected BS69. 
0µg, 0.05µg, 0.25µg, and 0.95µg of BS69 constructs were transfected per well. The 
negative controls consisted of HT1080 cells transfected with the reporter plasmid, an empty 
GAL4-DBD plasmid, and the empty pcDNA3-HA “stuffer” plasmid (not shown). The 
luciferase activity was then measured from the cell lysate, which was obtained 24 hours 
post-transfection. Results are normalized to total protein concentration as determined by 
Bradford assays, then reported as fold activation over the empty GAL4-DBD negative 
control. Significance markers are assigned in comparison to the activity of samples 
transfected with no BS69 within the respective group (Figure 3.16). 
The samples transfected with 0.95µg of BS69, regardless of the E1A construct being 
evaluated, all resulted in less luciferase activity than the other samples in their respective 
groups (Figure 3.16A). This could be a non-specific artefact caused by protein 
overexpression. Cells transfected with wildtype E1A showed a stepwise decline in 
luciferase activity when increasing concentrations of BS69, either full length or MYND,  
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Figure 3.16. The MYND domain of BS69 is necessary and sufficient in repressing 
E1A mediated transactivation. A) Luciferase assay showing BS69-mediated repression 
of E1A transactivation. Luciferase activity, shown as fold activation over the negative 
control is labelled on the Y-axis, while the relative amount and construct of BS69 
transfected is shown on the X-axis. HT1080 cells were co-transfected with 1µg of pGL2-
(UAS)6-Luc reporter, 0.05µg pM 13S Ad5 E1A or pM 13S E1A L115A, increasing 
concentrations of HA BS69, and pcDNA3 HA to ensure equal loading across all samples. 
Samples encoding an empty pM vector in place of E1A was used as the negative control 
(not shown). Cell lysates were collected 24 hours post transfection and the luciferase 
activity was measured. Results were normalized by protein concentration and reported as 
fold activity compared to the negative control. Results are shown as mean, n=2. 
Significance markers are assigned in comparison to the samples not transfected with a 
BS69 vector (ns = not significant; * p ≤ 0.05; one-way ANOVA with Dunnett’s multiple 
comparisons test). B) Western blot showing expression of BS69 constructs used in the 
luciferase assays. Cell lysates from the luciferase experiments were run on a western blot 
and probed using an anti-HA antibody to visualize the BS69 constructs, and anti-actin for 
the loading control. 
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were introduced. Increasing concentrations of full length BS69 resulted in a 27.3%, 56.7%, 
and 85.5% decrease in luciferase activity at 0.05µg, 0.25µg, and 0.95µg BS69 transfections 
respectively compared to cells not transfected with BS69, while increasing concentrations 
of MYND resulted in a 51.8%, 84.9%, and 97.2% decrease in luciferase activity at 0.05µg, 
0.25µg, and 0.95µg BS69 transfections respectively compared to cells not transfected with 
BS69. This change in activity was not observed with increasing concentrations of the No 
MYND BS69 construct, except for the sample transfected with 0.95µg of No MYND BS69. 
This sample showed a 54.6% decrease in activity compared to cells not transfected with 
BS69, albeit without statistical significance. Again, this result could be an artefact caused 
by the high levels of protein expression from this sample. These results suggest that the 
MYND domain is the primary mediator of repression of E1A transactivation.  
Unexpectedly, cells transfected with the L115A E1A mutant, which does not bind BS69 
efficiently, also showed a stepwise decline in luciferase activity with increasing 
concentrations of BS69 MYND. This resulted in a 13.8%, 69.1%, and 96.6% decrease in 
activity at 0.05µg, 0.25µg, and 0.95µg MYND transfections respectively compared to cells 
not transfected with BS69. Increasing concentrations of full length BS69 did not influence 
luciferase activity, except at the highest amount, 0.95µg, where the activity was decreased 
significantly by 49.5%. Increasing concentrations of No MYND BS69 had a similar effect 
on L115A E1A as it did on wildtype E1A, where the highest concentration sample showed 
a significant decrease of 62.4% in activity.  
Next, we wanted to see if the change in plasmid transfection concentration caused a 
stepwise increase in protein levels, so we ran the cell lysate on a western blot (Figure 
3.16B). BS69 MYND expressed very strongly, and showed the expected increase in protein 
levels. We could only detect full length BS69 on the western blot at the highest transfected 
concentration, and we were unable to detect the No MYND construct. The dark line 
separating the blot denotes a difference in exposure time of the chemiluminescent film, 
whereby the MYND domain was detectable within 5 seconds of exposure, while full length 
BS69 took approximately 15 minutes. This dramatic difference in expression levels 
between the full-length MYND construct and the MYND only construct may explain why 
residual repression activity was detected when MYND only construct was introduced into 
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samples transfected with the L115A E1A mutant. Actin was used as the loading control in 
these western blots (Figure 3.16B) 
 
3.2.3 Establishing the Conservation of the BS69 Mediated 
Repression of E1A Transactivation in HAdV-5, 12, and 40 
We have previously determined that adenovirus types 5, 9, and 12 from species C, D and 
A respectively are able to interact with BS69, while adenovirus types 3, 4, and 40 from 
species B, E, and F respectively could not. This observation may be due to the presence of 
the PXLXP motif in the E1A from adenovirus types able to interact with BS69, and the 
lack thereof on E1A from adenovirus types that are unable to interact with BS69. Thus, we 
set out to determine if the ability of E1A from a specific adenovirus species to bind to BS69 
is related to its sensitivity to BS69 mediated repression of E1A transactivation.  
We used a very similar protocol to the previous set of experiments, except we did not 
transfect any of these samples with 0.95µg of BS69. We co-transfected HT1080 cells with 
a GAL4-responsive luciferase reporter plasmid; a plasmid expressing 13S E1A from 
adenovirus types 5, 12, and 40, from species C, A, and F respectively, in a GAL4-DBD 
backbone; increasing concentrations of full length, MYND only, or NO MYND constructs 
of BS69 in the pcDNA3-HA backbone; and the pcDNA3-HA “stuffer” plasmid as 
necessary to ensure that 2µg of total DNA was transfected per sample (Figure 3.17). 0µg, 
0.05µg, and 0.25µg of BS69 constructs were transfected per well. The negative controls 
consisted of HT1080 cells transfected with the reporter plasmid, an empty GAL4-DBD 
plasmid, and the empty pcDNA3-HA “stuffer” plasmid (not shown). The luciferase activity 
was then measured from the cell lysate, which was obtained 24 hours post-transfection. 
Results are normalized to total protein concentration as determined by Bradford assays, 
then reported as fold activation over the empty GAL4-DBD negative control. Significance 
markers are assigned in comparison to the activity of samples transfected with no BS69 
within the respective group (Figure 3.17). 
Transfection of increasing concentrations of No MYND did not cause significant changes 
in luciferase activity in cells transfected with E1A from all three tested adenovirus types  
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Figure 3.17. Sensitivity to BS69 mediated repression of E1A transactivation is 
proportional to the relative binding affinity of the two proteins between different 
adenovirus species. Luciferase assay showing BS69-mediated repression of E1A 
transactivation. Luciferase activity, shown as fold activation over the negative control is 
labelled on the Y-axis, while the relative amount and construct of BS69 transfected is 
shown on the X-axis. HT1080 cells were co-transfected with 1µg of pGL2-(UAS)6-Luc 
reporter; 0.05µg pM 13S HAdV-5 E1A (A), pM 13S HAdV-12 E1A (B), or pM 13S 
HAdV-40 E1A (C); increasing concentrations of HA BS69; and pcDNA3 HA to ensure 
equal loading across all samples. Samples encoding an empty pM vector in place of E1A 
was used as the negative control (not shown). Cell lysates were collected 24 hours post 
transfection and the luciferase activity was measured. Results were normalized by protein 
concentration and reported as fold activity compared to the negative control. Results are 
shown as mean, n=2. Significance markers are assigned in comparison to the samples not 
transfected with a BS69 vector (ns = not significant; * p ≤ 0.05; one-way ANOVA with 
Dunnett’s multiple comparisons test). 
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(Figure 3.17). In cells transfected with HAdV-5 E1A, introducing 0.25µg of full length 
BS69 resulted in a 44.2% decrease in luciferase activity (Figure 3.17A). Furthermore, cells 
co-transfected with HAdV-5 E1A and 0.05µg or 0.25µg of MYND showed a 53.5% and 
82.2% decrease in luciferase activity respectively compared to cells not transfected with 
MYND. Cells transfected with HAdV-12 E1A showed higher sensitivity to increasing 
concentrations of full length BS69 and MYND compared to cells transfected with HAdV-
5 E1A (Figure 3.17B). When cells were transfected with 0.05µg and 0.25µg full length 
BS69, luciferase activity dropped by 34.9% and 57.8% respectively. For cells transfected 
with 0.05µg and 0.25µg MYND, luciferase activity dropped by 64.1% and 84.4% 
respectively. Lastly, cells transfected with HAdV-40 E1A are the least sensitive to BS69 
mediated repression (Figure 3.17C). Luciferase activity was not significantly different 
when transfected with increasing concentrations of full length BS69. Increasing 
concentrations of MYND decreased luciferase activity significantly, as transfecting 0.05µg 
and 0.25µg of MYND decreased luciferase activity by 34.4% and 63.5% respectively.  
E1A from HAdV-12 was most sensitive to BS69 mediated repression of transactivation, 
followed by HAdV-5, then HAdV-40. It is interesting to note that this pattern mirrors the 
relative binding affinity of E1A from these three adenovirus types, in that E1A from 
HAdV-12 binds most strongly to BS69, followed by HAdV-5, and finally HAdV-40 
(Figure 3.3A). 
 
3.2.4 Using siRNA to Knock Down Expression of BS69 in A549 
and IMR90 cells 
BS69 was recently found to be a specific reader of a histone H3 variant, histone H3.3, 
specifically trimethylated at Lysine residue 36 (H3.3K36me3) (Guo et al., 2014; Wen et 
al., 2014). BS69 also downregulates expression of target genes by two known mechanisms: 
suppression of transcriptional elongation and stimulation of intron retention (Guo et al., 
2014; Wen et al., 2014). Target genes have been identified by RNA-seq analysis, and 
verified using qPCR and western blotting (Guo et al., 2014; Wen et al., 2014). To verify 
the effects of BS69 on gene regulation, we first set out to knock down BS69 expression in 
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IMR90 and A549 cells. We chose to use IMR90 primary lung fibroblasts and the A549 
lung epithelial carcinoma cell line for this study because both cell types are susceptible to 
adenovirus infection and are widely used for these types of experiments.  
We transfected IMR90 and A549 cells using Silencer Select siRNAs (Thermo Fisher 
siRNA ID: s21153 and s21154) at a final concentration of 10nM 24 hours after being 
seeded into 6 well plates (Figure 3.18A). siRNA transfections were carried out using 
SiLenFect Lipid Reagent (BioRad) according to manufacturer’s protocol. Cells were then 
harvested 12, 24, and 48 hours post-transfection and analyzed by western blot. The siRNA 
knockdown was unsuccessful, as BS69 protein levels did not change with either of the 
transfected cells regardless of when the cells were harvested. Thus, we repeated the 
experiment with the following modifications: we increased the concentration of the 
siRNAs from 10nM to 20nM, combined both siRNAs in one of the samples, transfected 
A549 cells 4 hours after being seeded, harvested the cells 48 hours post-transfection, and 
used an siRNA for another target, PKA, as a positive control (Figure 3.18B). The PKA 
siRNA knockdown was successful, but BS69 protein levels still did not change. We 
repeated the experiment again using siRNA from another source, Dharmacon (SmartPool 
siRNA against ZMYND11), which contains four siRNA sequences as opposed to one from 
Silencer Select. We used 10nM or 20nM final concentration, transfected A549 cells 4 hours 
after being seeded, and harvested the cells 24 or 48 hours post transfection (Figure 3.18C). 
BS69 protein levels still did not change using any of these parameters.  
To ensure that my inability to detect knockdown of BS69 by siRNA was not related to a 
problem with antibody specificity, we transfected HT1080 cells with 0.5µg and 2µg of 
BS69-HA (Figure 3.19A). BS69 protein expression as detected by western blot with this 
anti-BS69 antibody increased as expected with increasing concentrations of transfected 
BS69. This suggests that the antibody is indeed specific for BS69. Next, we quantified 
BS69 mRNA transcript levels after siRNA knockdown using qPCR (Figure 3.19B). We 
transfected A549 cells with 20nM siRNA 4 hours after being seeded and harvested the cells 
48 hours post-transfection. Total RNA was extracted using the PureLink RNA Mini Kit 
(Thermo Fisher), then converted into cDNA using SuperScript VILO cDNA Synthesis Kit  
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Figure 3.18. siRNA knockdown of BS69 in IMR90 and A549 cells. A) IMR90 and 
A549 cells were transfected with 10nM of Silencer Select siRNA (siBS69 A: s21153; 
siBS69 B: s21154; Thermo Fisher) or a scrambled negative control (Silencer Negative 
Control No.2, Ambion) 24 hours after being seeded, and harvested 12, 24, and 48 hours 
post-transfection. Cell lysates were run on a western blot and the membrane was probed 
with anti-BS69 and anti-actin antibodies. B) A549 cells were transfected with 20nM total 
of Silencer Select siRNA (siBS69 A: s21153; siBS69 B: s21154; siPKA: s286; Thermo 
Fisher) or a scrambled negative control (Silencer Negative Control No.2, Ambion) 4 
hours after being seeded, and harvested 48 hours post-transfection. Cell lysates were run 
on a western blot and the membrane was probed with anti-BS69, anti-PKA, and anti-
tubulin antibodies. C) A549 cells were transfected with 10nM or 20nM total of 
Dharmacon siRNA (SmartPool siRNA against ZMYND11) or a scrambled negative 
control (Silencer Negative Control No.2, Ambion) 4 hours after being seeded, and 
harvested 24 or 48 hours post-transfection. Cell lysates were run on a western blot and 
the membrane was probed with anti-BS69, and anti-actin antibodies. 
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Figure 3.19. Verification of BS69 antibody specificity and BS69 siRNA induced 
mRNA transcript knockdown. A) HT1080 cells were transfected with 0.5µg and 2µg 
of HA-tagged BS69 24 hours after being seeded. Cell lysates were collected 24 hours 
post transfection. Samples were run on a western blot and the membrane was probed with 
anti-BS69 and anti-actin antibodies. B) A549 cells were transfected with 20nM total of 
Silencer Select siRNA (siBS69 A: s21153; siBS69 B: s21154; Thermo Fisher), 
Dharmacon siRNA (SmartPool siRNA against ZMYND11), or a scrambled negative 
control (Silencer Negative Control No.2, Ambion) 4 hours after being seeded, and 
harvested 48 hours post-transfection. Total RNA was extracted and 1µg was used reverse 
transcribed into cDNA. BS69 transcript levels were quantified using qPCR with SYBR 
Green. Results were analyzed using the 2-ΔΔCT method, using GAPDH as the internal 
control and normalizing data to that of cells transfected to scrambled siRNA. Results are 
shown as values from a single experiment using technical triplicates. 
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(Thermo Fisher) according to manufacturer’s protocol. cDNA quantification was 
completed using Power SYBR Green PCR Master Mix kit (Thermo Fisher). Results were 
obtained using the 2-ΔΔCT method (Livak & Schmittgen, 2001), using GAPDH as the 
internal control and normalizing the data to that of cells transfected with the scrambled 
siRNA control. All samples transfected with BS69 siRNA showed an approximate 50% 
decrease in mRNA transcript levels. Thus, the siRNA knockdown is indeed working to 
decrease BS69 transcript levels. These results suggest that a long half-life and subsequent 
low protein turnover rate of BS69 may be the reason why I could not knockdown BS69 
protein levels using siRNA. 
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4 Discussion 
 
4.1 Mapping the Interaction between E1A and BS69 
4.1.1 Using Homology Modelling to Construct a Structural 
Prediction of the MYND Domain of BS69 
Homology modelling and protein-ligand docking were used to visualize the molecular 
determinants of the interaction between E1A and BS69. The model was developed to aid 
in the design of an E1A mutant incapable of binding with BS69. Within a few months after 
the construction of our homology model, another group published an NMR structure of the 
BS69 MYND domain interacting with a peptide from the EBV oncoprotein, EBNA2 
(Harter et al., 2016). The EBNA2 peptide contains significant sequence similarity to the 
PXLXP motif in E1A. Ultimately, both the NMR structure and the homology model were 
used during the design of our E1A point mutants (Figure 3.7A).  
Homology modelling with protein-ligand docking is an alternative method to protein co-
crystallization or NMR in determining the binding surface of a protein-peptide interaction. 
Using this in silico method is advantageous in that results may be obtained relatively 
quickly, so high-throughput modelling is possible. This method may also be used when 
working with structures that are challenging to produce using either protein crystallization 
or NMR. Accuracy of these in silico models is also consistently improving with every 
iteration of modelling and docking software (Kozakov et al., 2013). However, any 
conclusions drawn about the interaction surface from computer modelling must still be 
verified using other experimental techniques.  
One of the challenges in constructing the BS69 MYND – E1A model was choosing the 
appropriate template, as every member of the ZMYND family of proteins contain two 
amino acids between cysteine residues c1b and c2b except for BS69 and ZMYND8, which 
does not currently have a published structure (Figure 3.1A). These two amino acids 
between the cysteine residues may function as a spacer, so that the cysteine side chains can 
more easily achieve the necessary conformation to coordinate a zinc ion and achieve proper 
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protein folding. This phenomenon is seen in the three MYND domain models shown in 
Figure 12, where the dihedral angles for the cysteine and surrounding residues are more 
strained for the BS69 MYND NMR structure and the homology structure compared to 
ZMYND5, which has the two spacer residues (Figure 4.1). The contour lines on this 
Ramachandran plot denote the boundary by which 98% or 99.5% of 81,213 non-glycine, 
non-proline, and non-pre-proline residues from a library of 500 proteins reside (Figure 4.1) 
(Lovell et al., 2003). Residues within the 98% contour line are “favoured”, while residues 
inside the 99.5% contour line are “allowed”; residues outside of the 99.5% contour line are 
disallowed due to steric hindrance, unless the residues are glycine, proline, or pre-proline. 
On the Ramachandran plot, both cysteine residues in the ZMYND5 structure are within the 
“favoured” region, while only one cysteine residue is within the “favoured” region for the 
homology model. In contrast, and both cysteine residues are outside the “favoured” region 
for the BS69 MYND NMR structure. Although all residues within all three structures have 
dihedral angles that are sterically allowed, the BS69 MYND domain is more strained in 
this region than ZMYND5 possibly due to the presence of the spacer residues contributing 
to higher flexibility.  
There were two major discrepancies between the computer-generated BS69 MYND model 
and the NMR model: the leucine sidechain in the PXLXP motif protrudes away from the 
MYND domain in the homology model, while this sidechain points toward the MYND 
domain in the NMR model; and the E1A peptide in the homology model is in the opposite 
orientation compared to the EBNA2 peptide of the NMR model (Figure 3.2). Interestingly, 
there are a few examples of protein-protein interactions being compatible in opposite 
orientations such as in Src Src homology 3 (SH3) domain and SUMO-1 binding to their 
respective binding partners (Feng et al., 1994; Song et al., 2005).  Although the PXLXP 
motif is palindromic, it is unlikely that the E1A-BS69 peptide-protein interaction can occur 
in both N-C and C-N orientations as this phenomenon is exceedingly rare. The L115 
residue is experimentally determined to be important for this interaction, both by myself 
and others, so it is more likely that the side chain of this residue would be facing towards 
the MYND domain to facilitate this interaction (Ansieau & Leutz, 2002; Harter et al., 
2016). The differences between the in silico model and the NMR structures may be caused  
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Figure 4.1. Ramachandran plots of the MYND domain structures of ZMYND5 and 
BS69. Ramachandran plots of the A) NMR structure of the BS69 MYND domain (PDB: 
5HDA), B) NMR structure of ZMYND5 MYND domain (PDB: 2ODD), and C) 
homology model of BS69 MYND domain (Harter et al., 2016; Liu et al., 2007). Points in 
red denote the dihedral angles of the cysteine residues that either have the two spacer 
residues (NMR model of ZMYND5), or do not have the two spacer residues (NMR or 
homology model of BS69 MYND). Contour lines in green show the boundary in which 
residues are “favoured” (within 0.02, or 98%), or “allowed” (within 0.0005, or 99.5%). 
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by several factors. The Cluspro protein-ligand docking webserver uses rigid-body docking, 
in that the bond angles and lengths of the receptor, or BS69 MYND, are fixed (Kozakov et 
al., 2017). This method of docking may not be sufficient for some interactions, as some 
proteins exhibit slight shifts in conformation upon binding to a ligand. Additionally, the 
E1A peptide was docked to a homology model of the BS69 MYND domain, which may 
not have been generated in a conformation conducive to binding with E1A. Flexible 
docking, where the receptor may undergo conformational changes, may ameliorate some 
of these problems, but this procedure takes considerably more computing time (Cerqueira 
et al., 2009).  
Although I referred primarily to the BS69-EBNA2 model during the design of our E1A 
mutants, homology modelling with protein-ligand docking still served as a valuable tool to 
validate various aspects of the BS69-E1A interaction surface. For example, the leftmost 
proline residue in all three structures show similar bond angles and spatial orientation, with 
the side chain protruding towards the MYND domain (Figure 3.2). The consistency 
between the models is a hint that this proline residue may play an important role in the 
peptide-protein interaction. The yeast two-hybrid assays using the alanine scanning panel 
confirm that this residue is crucial in the E1A-BS69 interaction (Figure 3.6). Thus, 
homology modelling is helpful in both predicting and validating the molecular 
determinants of a protein-peptide interaction.  
 
4.1.2 Determining the Conservation of Interaction Between BS69 
and E1A of Human Adenovirus Species A-F 
Using yeast two-hybrid assays, I determined that E1A from HAdV-5, 9, and 12 of species 
C, D, and A respectively can bind to BS69, while E1A from HAdV-3, 4, and 40 of species 
B, E, and F cannot (Figure 3.3A). It is unknown if E1A from HAdV-52, the newest 
characterized adenovirus type from species G, is able to interact with BS69, but it is 
unlikely as E1A from that species does not contain the PXLXP motif (Figure 1.3). Thus, 
the interaction between E1A and BS69 is fairly conserved amongst different adenovirus 
species, and may have an important functional role during an adenovirus infection.  
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The PXLXP motif was identified by the Leutz lab through sequence comparison and co-IP 
assays of BS69 with E1A and EBNA2 (Ansieau & Leutz, 2002). As expected, this motif 
is present in E1A proteins able to bind BS69, and absent or truncated in E1A proteins from 
HAdV species unable to bind BS69 (Figure 3.3B). Unexpectedly, the sequence alignment 
shows that the location of the PXLXP motif in HAdV-9 E1A is located upstream compared 
to the motif of HAdV-5 E1A, yet both proteins can bind BS69 (Figure 3.3B). HAdV-12 
E1A also contains two PXLXP motifs (Figure 1.3), but the C-terminal motif alone is 
sufficient to mediate an interaction with BS69. The HAdV-12 E1A construct I used is 
missing the first proline residue of the N-terminal motif (Figure 3.3B). EBNA2 from EBV 
contains two PXLXP motifs in CR7 and CR8 spanning residues 377-391 and residues 437-
450 respectively, and both these motifs can bind to BS69 (Harter et al., 2016). It is not 
known if both PXLXP motifs within HAdV-12 can coordinate interactions with two BS69 
molecules concurrently. However, this is unlikely because the motifs are very close 
together, with only 10 amino acids between the motifs (Figure 1.3). Evidently, the location 
of the PXLXP motif within the protein is not important in its ability to facilitate an 
interaction with BS69, and my observations highlight the modularity of the SLiMs within 
these two viral proteins. 
 
4.1.3 Defining the Minimal Interacting Region and Specific 
Residues of E1A Required to Bind with BS69 
By using the E1A truncation panel in a series of yeast two-hybrid assays, I found that E1A 
residues 112-119, with the sequence MPNLVPEV, is the minimal interacting region 
required to bind strongly to BS69. Furthermore, using an alanine scanning mutagenesis 
panel, I found that E1A residues P113 and L115 are crucial in mediating a strong 
interaction (Figure 3.6B). I also found that the S111A mutation also resulted in modestly 
decreased, albeit not significant, interaction strength between E1A and BS69. This 
observation is also present in the truncation mutation panel, as the peptides containing the 
N-terminal serine residue exhibit higher binding activity compared to the peptides with the 
serine truncated (Figure 3.4A). Thus, I have identified three residues within E1A CR2 that 
are important for interacting with BS69. 
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To facilitate the truncation mutation analysis, a short peptide linker was used to bridge the 
GAL4 DBD and the E1A truncation mutants in the bait protein (Figure 3.5). We chose to 
use SGG as the linker sequence because glycine residues are more flexible compared to 
other amino acids due to their lack of a β-carbon, while serine was chosen for the small 
side chain and hydroxyl group to enhance solvation. The linker was included to avoid steric 
effects between the GAL4 DBD and the BS69 MYND domain that could potentially hinder 
the interaction between the E1A peptide and BS69 in this system. I have shown that adding 
the linker increases β-galactosidase activity of our E1A constructs by approximately 100 
Miller units (Figure 3.5). The length of the linker is also sufficient, as the first significant 
drop in activity was observed when a C-terminal residue of the truncation mutant was 
removed (T4 and T5, Figure 3.4A). Thus, the decreased in activity was not caused by BS69 
shifting closer the GAL4 DBD as the E1A peptide was being truncated.  
Most of the mutations generated by alanine scanning did not have a significant impact on 
the binding affinity between E1A and BS69 (Figure 3.6). Yet, truncating some of these 
residues, such as V119 and M112, caused the binding affinity between E1A and BS69 to 
significantly decrease (Figure 3.4A). This may be due to these valine and methionine 
residues playing a role in binding with BS69, but not requiring high sequence stringency. 
From these observations, alanine scanning mutagenesis is not sufficient in determining all 
the residues involved in a protein-peptide interaction. Alanine residues can also mediate 
van der Waals interactions similarly to methionine and valine residues, so mutating these 
residues to alanine may not cause a detectible change in binding affinity. Although glycine 
residues are less capable than alanine in facilitating these intermolecular interactions, the 
lack of a β-carbon enables glycine residues to form conformations that other amino acids 
cannot; thus, glycine was not used in this mutation panel.  
Double and triple E1A point mutants were constructed to improve upon the previously 
published L115A mutant, as the L115A construct shows some residual interaction with the 
MYND domain of BS69 in our luciferase assays (Figure 3.16A) (Ansieau & Leutz, 2002). 
The amino acids being targeted were chosen by referring to the NMR structure of EBNA2 
in complex with the MYND domain of BS69 and our E1A-BS69 homology model (Harter 
et al., 2016). E1A residues M112, P113, L115, and P117 were targeted for mutation, as the 
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equivalent EBNA2 residues protrude towards the MYND domain in the NMR structure. 
Because all our double and triple point mutants showed no activity, we ran a western blot 
to ensure the bait and prey proteins were being sufficiently expressed (Figure 3.7C). We 
found that all proteins in all samples were expressed as expected, except for the M12 bait 
protein. Therefore, a more sensitive assay should be used for future studies to measure the 
interaction between these mutants and BS69. The M13 mutant is a good candidate to 
proceed with future experimentation, as this construct expresses well and contains the 
P113A and L115A mutations – both of which were separately identified to decrease the 
binding affinity between E1A and BS69 using the alanine scanning yeast two-hybrid assays 
(Figure 3.6, 3.7). 
In summary, I found that E1A residues P113 and L115 are strongly involved in the 
interaction with BS69, while residues S111, M112, and V119 have an ancillary role. 
Unexpectedly, mutating P117, which is the C-terminal proline of the PXLXP motif, did 
not change the interaction strength between E1A and BS69 (Figure 3.14B). Although we 
found several amino acids to target in future studies, it is important to ensure that these 
residues are not involved in neighbouring E1A interactors. The EVIDLT and LXCXE 
motifs used by E1A to interact with UBC9 and pRb/STING respectively are downstream 
of the PXLXP motif (Figure 1.6) and there are no known interaction motifs immediately 
upstream of the PXLXP motif. These neighbouring interacting partners may also be 
competing with BS69 to bind E1A CR2 in the truncation mutation assays, resulting in 
decreased activity of the CR2 control sample compared to E1A truncation mutants that do 
not contain the EVIDLT and LXCXE motifs (Figure 3.4A). The M13 double point mutant 
is a promising candidate for future experiments, as there are only two residues targeted for 
mutation, the mutations are conservative, and the targets are closer to the N-terminus and 
therefore more distant from the EVIDLT and LXCXE motifs.  
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4.1.4 Mapping the E1A-BS69 Binding Surface Using a Peptide 
Array 
Peptide arrays were used to further characterize the interaction surface between BS69 and 
E1A. By using positional scanning, we mutated every position on the E1A peptide to every 
other residue. This technique allows us to precisely probe the BS69 minimal interacting 
region to determine the sequence stringency needed to facilitate a strong interaction with 
BS69. Unlike yeast two-hybrid assays, peptide arrays use purified proteins and peptides, 
and can thus measure direct protein-peptide interactions. Peptide arrays are also an 
especially powerful tool for studying E1A interactions, as E1A is intrinsically disordered 
in all but CR3 and is composed of densely-packed interaction motifs (Figure 1.6). Although 
these arrays allow for high-throughput screening of a protein-peptide interaction, there are 
also several constraints. Yeast two-hybrid and co-IP assays can both measure interactions 
between two globular proteins, while peptide arrays are restricted to protein-peptide 
interactions. Peptide arrays are also limited in that the peptides may only be up to a 
maximum length, approximately 15 residues, before sequence fidelity declines due to the 
compounding effect of peptide synthesis efficiencies. The protein-peptide interaction also 
takes place in PBS, which does not accurately mimic the constituents of a cellular 
environment. The high concentration of the proteins and peptides used in a peptide array 
experiment are also a concern, as signals detected from a peptide array may not accurately 
depict the interactions formed in a cellular environment. Thus, results of a peptide array 
must be verified using other more biologically relevant techniques, such as co-IP. 
Nevertheless, peptide arrays are a powerful and flexible tool to comprehensively and 
systematically study protein-peptide interactions, and are especially suitable for 
intrinsically disordered proteins containing SLiMs, such as E1A.  
Protein purification of GST- and 6xHis- tagged BS69 were completed using affinity 
chromatography. I have also purified GST-tagged pRb and UBC9, which are E1A binding 
partners that interact with SLiMs neighbouring the PXLXP motif, in preparation for future 
peptide array experiments (Figure 3.10). The BS69 MYND domain was chosen to be our 
target to purify, as my preliminary experiments showed that purifying the MYND domain 
instead of full length BS69 resulted in fewer degradation products (not shown). Coomassie 
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Blue staining of purified 6xHis tagged BS69 MYND revealed protein bands at 75kDa, 
50kDa, 25 kDa, and 20 kDa, with the 25kDa band being the most prominent (Figure 3.8A). 
The 75kDa and 50kDa bands reflect polymers of the MYND domain, while the 20kDa 
band could be a degradation product. A western blot of the same sample showed a similar 
laddering effect, with bands at 25kDa, 50 kDa, 75 kDa, 100kDa, and 125 kDa, which 
further affirms the presence of protein polymers or aggregates (Figure 3.8B). Aggregation 
and degradation may have been caused by a shortage of zinc in the media, as each molecule 
of BS69 MYND coordinates two zinc ions. Lack of zinc may have caused multiple 
molecules of MYND to share zinc ions, or caused degradation due to protein misfolding. 
To ameliorate this problem, I supplemented the growth media with 100µM ZnCl during 
the next round of protein purification. Addition of ZnCl did not alter the purification profile 
of 6xHis-tagged BS69, and may have negatively impacted purification by competing with 
the Nickel-NTA substrate to bind the 6xHis tag (Figure 3.9). I concurrently purified GST-
tagged BS69 MYND, which appeared as a single band at 47kDa in the Coomassie Blue gel 
(Figure 3.9). Due to time constraints, 6xHis-tagged BS69 was used to probe the peptide 
array, but future experiments should be conducted using GST-tagged BS69 MYND due to 
better protein purity, lack of protein aggregation, and fewer degradation products. 
Background signal was very high for the peptide array experiments using peptides both 
HAdV-5 and HAdV-12 E1A. E1A from HAdV-12 can also bind BS69, so we chose to use 
this E1A both as a positive control and to determine if the interaction mechanism is similar 
in other adenovirus species. We expected the wildtype peptide sequences (circled in red) 
to produce the strongest signal, but these spots displayed similar intensities to most other 
spots on the membrane (Figure 3.11). Unexpectedly, peptides with residues sequentially 
mutated to arginine produced the strongest signal in both HAdV-5 and HAdV-12 E1A 
arrays when probed with anti-His and anti-BS69 antibodies (Figure 3.11, 3.12). These 
signals were not present when the membranes were stripped and re-probed with anti-His 
antibody without first incubating the array with purified His-MYND (Figure 3.13). Thus, 
these signals may have resulted from nonspecific binding of the protein to the peptides on 
the membrane. The anti-His antibody also contributed to some background signal, shown 
by the image of the stripped membrane (Figure 3.13). In future experiments, the GST-
tagged BS69 MYND should be used in place of His-tagged BS69 to improve the quality 
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of purified protein, and more stringent wash protocols should also be used to minimalize 
background signals. The sequence fidelity of the peptides synthesized on the membrane 
should also be evaluated.  
 
4.1.5 Verifying the E1A-BS69 Interaction Using Co-
Immunoprecipitation Assays 
I verified the interaction between E1A and BS69 in a mammalian cell culture system using 
co-IP assays. Although E1A CR2 was sufficient to form an interaction between BS69, full 
length E1A pulls down BS69 more efficiently (Figure 3.14). Thus, there appears to be other 
regions within E1A used to facilitate the interaction with BS69. There is conflicting data 
in the literature about the involvement of CR3 in this interaction. The Bernards group found 
that CR3 is the main region by which E1A uses to facilitate its interaction with BS69 
(Hateboer et al., 1995). However, the Leutz group found that 13S and 12S E1A both bound 
BS69 equally as well (Ansieau & Leutz, 2002). The Bernards group used murine BS69, 
while the Leutz group used human BS69 in their respective co-IP experiments. BS69 is 
highly conserved between humans and mice, with 14 amino acid changes in total between 
these species (Figure 1.9). The BS69 MYND domain sequence is identical in human and 
mice, and most of the variation is located between the PWWP domain the and the MYND 
domain. It is possible that regions other than the MYND domain of murine BS69 interacts 
with CR3 of E1A, but the same regions in human BS69 does not interact with E1A. To 
determine if CR3 enhances the ability of E1A to bind to BS69, I created the CR2-CR3 E1A 
truncation mutant. Unexpectedly, this E1A construct showed decreased binding strength 
compared to both CR2 and full length E1A (Figure 3.14) This observation may be caused 
by improper protein expression of this E1A construct, or misfolding of CR3. 
Co-IP assays should also be used to verify the interaction data obtained from the previous 
yeast two-hybrid experiments. Yeast two-hybrid assays are more sensitive than co-IP in 
that two-hybrid assays can detect transient interactions, and the proteins of interest in two-
hybrid assays are relocalized to the nucleus. Thus, two-hybrid assays may detect 
interactions that would not normally occur under mammalian physiological conditions due 
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to differences in subcellular localization or binding affinity. Optimally, co-IP assays should 
be conducted using endogenous proteins instead of using a vector to express the proteins 
of interest. The proteins I expressed in the co-IP assays are tagged with either HA or GFP, 
and these tags may alter the binding affinity between the E1A constructs and BS69. 
Furthermore, overexpressing proteins from a plasmid alters the concentrations and 
stoichiometric balance of the proteins of interest. Thus, co-IP assays using overexpressed 
proteins may also produce interactions that do not occur under physiological conditions. In 
future experiments, it would be prudent to use co-IP assays with endogenous proteins, with 
E1A mutants introduced via adenovirus infections. Mutant adenovirus may also display 
altered growth and infectivity, so precautions must be taken to control these variables. 
Select single and double E1A point mutants showing altered binding affinity to BS69, such 
as M1, M3, M5, and M13, should be included in these future interaction studies to verify 
these observations in a mammalian cell culture system. 
 
4.2 Analysis of BS69 Mediated Changes in E1A 
Transactivation 
4.2.1 Determining the Region of BS69 Responsible for Changes in 
E1A Mediated Transactivation 
Using luciferase assays in HT1080 cells, I have shown that BS69 decreases E1A mediated 
transactivation in a dose dependent manner. These observations agree with the results 
published by the Bernards group (Figure 3.15) (Hateboer et al., 1995). I have also shown 
that this repression of E1A transactivation requires an intact PXLXP motif, as 
transactivation by the E1A L115A mutant was not significantly changed by increasing 
concentrations of BS69 (Figure 3.15). This observation is consistent with the results found 
by the Leutz lab, although their experiments were performed in the opposite orientation 
whereby E1A was used to neutralize BS69-mediated gene repression (Ansieau & Leutz, 
2002). With increasing concentrations of BS69, the luciferase activity of the L115A mutant 
also steadily decreased, albeit not significantly. Thus, there may be another region in E1A 
that interacts with BS69, or the L115A mutant does not completely abrogate binding 
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between CR2 and the MYND domain of BS69. The use of the double mutant, such as 
P113A and L115A, that exhibits a more complete binding defect in this assay may help 
resolve this question. 
To determine if the MYND domain of BS69 was necessary and sufficient to repress E1A 
transactivation, I repeated the previous experiments and added increasing concentrations 
of BS69 MYND (residues 427-602) and BS69 No MYND (residues 46-426) constructs 
(Figure 3.16). Transfecting cells with 0.95µg of BS69, regardless of construct, resulted in 
significantly decreased luciferase activity in almost all samples. This phenomenon is likely 
due to a technical error during the experiment causing protein overexpression, so 
discussion will proceed omitting these results. In this set of experiments, L115A E1A 
displayed overall greater luciferase activity compared to wildtype E1A. This may be caused 
by endogenous BS69 inhibiting wildtype E1A transactivation, but not influencing 
transactivation by L115A E1A. As expected, adding increasing concentrations of full 
length BS69 mirrored the results from our previous experiment, and adding increasing 
concentrations of No MYND BS69 did not significantly change transactivation ability of 
both wildtype and L115A E1A. Therefore, the MYND domain of BS69 is essential in 
BS69-mediated inhibition of E1A transactivation. In samples with wildtype E1A, 
increasing concentrations of BS69 MYND caused a decrease in E1A mediated 
transactivation at a faster rate than full length BS69. This is likely due to the higher level 
of protein expression by the BS69 MYND compared to full length BS69 at the same 
transfection concentration (Figure 3.16B). The smaller MYND domain by itself may also 
be more accessible to E1A compared to full length BS69, as the other globular domains of 
BS69 may either introduce steric hindrance to the promoter region of the reporter plasmid, 
or be used to bind to other host factors and be recruited away from E1A. Unexpectedly, 
adding BS69 MYND also caused a decrease in transactivation by the L115A E1A mutant. 
Again, this observation is likely caused by increased BS69 MYND expression or 
accessibility to E1A. The L115A mutant binds to BS69 with much less affinity compared 
to wildtype E1A; however, an interaction may still occur with sufficiently high protein 
concentrations. To better understand these observations, protein expressions levels should 
be consistent between the different BS69 constructs in future experiments, and another 
E1A mutant should be used to completely abrogate the interaction with BS69.  
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4.2.2 Establishing the Conservation of BS69 Mediated Repression 
of E1A Transactivation in HAdV-5, 12, and 40 
Using luciferase assays and various adenovirus types, I showed that E1A proteins from 
species with greater binding affinity to BS69 are more susceptible to BS69 mediated 
repression of E1A transactivation. E1A from HAdV-12 binds with the greatest affinity to 
BS69, followed by HAdV-5, then HAdV-40 (Figure 3.3). BS69-mediated repression of 
E1A transactivation follows the same pattern, where E1A from HAdV-12 is most sensitive, 
followed by HAdV-5 and finally HAdV-40 (Figure 3.17). This phenomenon is most clearly 
illustrated in samples transfected with full length BS69, where HAdV-12 E1A 
transactivation is significantly inhibited by low and high concentrations of full length 
BS69, HAdV-5 E1A is only significantly inhibited by high concentrations of full length 
BS69, and HAdV-40 E1A is not significantly affected by full length BS69. As expected, 
increasing levels of BS69 No MYND had no significant effect on transactivation by E1A 
from any of the tested adenovirus types. 
E1A from these adenovirus types also display dramatically different levels of 
transactivation. When these samples were not co-transfected with BS69, E1A from HAdV-
12 produced the highest level of transactivation, followed by HAdV-40, and finally HAdV-
5. These observations agree with previously published results from the Mymryk lab 
(Ablack et al., 2010). E1A CR3 is a zinc finger domain, and can facilitate transactivation 
on its own when fused to a DBD (Ablack et al., 2010). E1A CR3 is the most conserved 
domain between different adenovirus species, yet transactivation ability between 
adenovirus species varies dramatically. This may be caused by different mechanisms 
between species by which CR3 facilitates transactivation, but this may also be caused by 
unique ways in which E1A from different adenovirus species are regulated. Here, I have 
also shown that BS69 differentially affects E1A transactivation from different adenovirus 
species in a manner that is dependent on the interaction strength between E1A and BS69. 
Thus, the ability of BS69 to repress E1A dependent transactivation may contribute to some 
of the observed differences in transactivation between HAdV species.  
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4.2.3 Knockdown of BS69 in A549 and IMR90 Cells 
To proceed with future experiments to study other physiological processes influenced by 
the E1A-BS69 interaction, such as how E1A affects BS69-mediated gene regulation and 
how BS69 affects adenovirus growth, it is first necessary to create a cell line that does not 
express BS69. Human BS69 is ubiquitously expressed in all tissues and localized to the 
nucleus, and there is no commercially available cell line to our knowledge that does not 
express BS69 (Velasco et al., 2006). We chose to knock down BS69 in IMR90 primary 
cells and the A549 cell line due to their susceptibility to adenovirus infection for future 
experiments. I was unable to knock down BS69 using siRNA from ThermoFisher or 
Dharmacon (Figure 3.18) in either of the two cell lines. I showed the experimental 
technique and reagents were working as intended by successfully knocking down PKA 
(Figure 3.18B), ensuring the antibody was specific to BS69 (Figure 3.19A), and verifying 
the reduction of BS69 transcript levels (Figure 3.19B). Other groups have attempted to 
knock down BS69 as well, but most have used short hairpin RNA (shRNA) delivered using 
a lentiviral vector (Guo et al., 2014; Wen et al., 2014). Another group used siRNA to knock 
down BS69, but only transcript levels were shown (Mackmull et al., 2015). siRNA 
knockdowns are short-term, while shRNA knockdown via a lentiviral gene delivery system 
is long-term. Thus, the reason why my siRNA knockdowns were unsuccessful could be 
due to BS69 having a long half-life. In future attempts, clustered regularly interspaced short 
palindromic repeats (CRISPR) genome editing or shRNA should be used to create BS69 
knockout cell lines.    
 
4.3 Summary of Findings and Future Directions 
This project has revealed several interesting observations about the interaction between 
E1A and BS69. Firstly, I found that this interaction is conserved in HAdV-5, 9, and 12 of 
species C, D, and A respectively, and is absent in HAdV-3, 4, and 40 of species B, E, and 
F respectively. This finding also confirms the importance of the previously described 
PXLXP motif, as adenoviruses that have this motif within E1A can bind BS69, while 
adenoviruses that lack the motif are not able to bind BS69 (Ansieau & Leutz, 2002). The 
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minimal interacting region was also defined as residues 112-119 in HAdV-5 E1A, with 
P113 and L115 having the most important roles in this interaction. S111, M112, and V119 
of HAdV-5 E1A also contribute to this interaction, but these residues play an ancillary role. 
Additionally, I found that full length E1A binds to BS69 with greater affinity than CR2 
alone. However, it is still unclear if CR3 plays a role in the interaction between E1A and 
BS69 despite conflicting data in the literature (Ansieau & Leutz, 2002; Hateboer et al., 
1995). A future direction of this interaction study would be to probe the remaining regions 
of E1A to discover other BS69 interacting sites. Furthermore, more experiments should be 
completed to determine the relative binding affinity of the E1A double and triple point 
mutants with BS69, as well as neighbouring binding partners such as pRb, UBC9, and 
STING. Peptide arrays are a powerful tool that may accelerate this process, with the benefit 
of confirming that the interaction between E1A and BS69 is direct. These experiments will 
ultimately help find an E1A mutant that completely and cleanly abrogates binding with 
BS69 without perturbing the interaction with other target proteins.  
Consistent with previous results, I have also confirmed that BS69 is a potent inhibitor of 
E1A transactivation, and that this function of BS69 is dependent on the fidelity of the 
PXLXP motif on E1A (Ansieau & Leutz, 2002). Inhibition by BS69 is also dose-
dependent, as higher concentrations of BS69 resulted in lower transactivation ability of 
E1A. The C-terminal MYND domain of BS69 is both necessary and sufficient to inhibit 
E1A transactivation. I have also found that BS69-mediated inhibition of E1A 
transactivation is conserved in HAdV-5, 12, and, 40, with HAdV-5 having the greatest 
sensitivity and HAdV-40 being the least sensitive. It was surprising to find that 
transactivation by HAdV-40 E1A was affected by BS69, as CR2 from this E1A did not 
bind to BS69 according to my yeast two-hybrid experiments. Thus, other regions of E1A 
may facilitate the interaction between E1A and BS69 in HAdV-40, or the high 
concentration of the BS69 MYND construct within this luciferase system resulted in an 
experimental artefact. In future experiments, it would be prudent to use a double or triple 
E1A point mutant in these luciferase assays, and to ensure that the expression levels of the 
different BS69 truncation mutants are more consistent. 
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With the successful mapping of an interaction site between E1A and BS69, a future 
direction of this project involves the generation of a cell line that does not express BS69. 
Using siRNA to knock down BS69, which has a low protein turnover rate, is not effective, 
so other methods should be used instead. For example, using CRISPR or shRNA may yield 
more fruitful results, as these methods are permanent while the effects of siRNA are 
transient. After generating a BS69 knockout cell line, we will be able to measure the impact 
of the E1A-BS69 interaction on viral growth and regulation of host and viral gene 
expression. BS69 is a histone reader that downregulates genes that are decorated by histone 
H3.3K36me3 (Guo et al., 2014; Wen et al., 2014). Other studies have also shown that BS69 
fused to GAL4 DBD represses transcription in a luciferase system, and that E1A 
neutralizes BS69-mediated gene repression (Masselink & Bernards, 2000). It would be 
interesting to see if E1A is able to abrogate BS69-mediated gene repression at the 
epigenetic level, and to discover the mechanism by which this occurs.  
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